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A B S T R A C T
Background
Exercise programmes are a relatively inexpensive, low-risk option compared with other, more invasive therapies for treatment of leg
pain on walking (intermittent claudication (IC)). This is the fourth update of a review first published in 1998.
Objectives
Our goal was to determine whether an exercise programme was effective in alleviating symptoms and increasing walking treadmill
distances and walking times in people with intermittent claudication. Secondary objectives were to determine whether exercise was
effective in preventing deterioration of underlying disease, reducing cardiovascular events, and improving quality of life.
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched 15 November 2016) and
the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10) via the Cochrane Register of Studies Online, along
with trials registries.
Selection criteria
Randomised controlled trials of an exercise regimen versus control or versus medical therapy for people with IC due to peripheral arterial
disease (PAD). We included any exercise programme or regimen used for treatment of IC, such as walking, skipping, and running.
Inclusion of trials was not affected by duration, frequency, or intensity of the exercise programme. Outcomemeasures collected included
treadmill walking distance (time to onset of pain or pain-free walking distance and maximum walking time or maximum walking
distance), ankle brachial index (ABI), quality of life, morbidity, or amputation; if none of these was reported, we did not include the
trial in this review.
Data collection and analysis
For this update (2017), RAL and AH selected trials and extracted data independently. We assessed study quality by using the Cochrane
’Risk of bias’ tool. We analysed continuous data by determining mean differences (MDs) and 95% confidence intervals (CIs), and
dichotomous data by determining risk ratios (RRs) and 95% CIs. We pooled data using a fixed-effect model unless we identified
significant heterogeneity, in which case we used a random-effects model. We used the GRADE approach to assess the overall quality of
evidence supporting the outcomes assessed in this review.
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Main results
We included two new studies in this update and identified additional publications for previously included studies, bringing the total
number of studies meeting the inclusion criteria to 32, and involving a total of 1835 participants with stable leg pain. The follow-up
period ranged from two weeks to two years. Types of exercise varied from strength training to polestriding and upper or lower limb
exercises; supervised sessions were generally held at least twice a week. Most trials used a treadmill walking test for one of the primary
outcome measures. The methodological quality of included trials was moderate, mainly owing to absence of relevant information. Most
trials were small and included 20 to 49 participants. Twenty-seven trials compared exercise versus usual care or placebo, and the five
remaining trials compared exercise versus medication (pentoxifylline, iloprost, antiplatelet agents, and vitamin E) or pneumatic calf
compression; we generally excluded people with various medical conditions or other pre-existing limitations to their exercise capacity.
Meta-analysis from nine studies with 391 participants showed overall improvement in pain-free walking distance in the exercise group
compared with the no exercise group (MD 82.11 m, 95% CI 71.73 to 92.48, P < 0.00001, high-quality evidence). Data also showed
benefit from exercise in improved maximum walking distance (MD 120.36 m, 95% CI 50.79 to 189.92, P < 0.0007, high-quality
evidence), as revealed by pooling data from 10 studies with 500 participants. Improvements were seen for up to two years.
Exercise did not improve the ABI (MD 0.04, 95% CI 0.00 to 0.08, 13 trials, 570 participants, moderate-quality evidence). Limited
data were available for the outcomes of mortality and amputation; trials provided no evidence of an effect of exercise, when compared
with placebo or usual care, on mortality (RR 0.92, 95% CI 0.39 to 2.17, 5 trials, 540 participants, moderate-quality evidence) or
amputation (RR 0.20, 95% CI 0.01 to 4.15, 1 trial, 177 participants, low-quality evidence).
Researchers measured quality of life using Short Form (SF)-36 at three and six months. At three months, the domains ’physical
function’, ’vitality’, and ’role physical’ improved with exercise; however this was a limited finding, as it was reported by only two trials.
At six months, meta-analysis showed improvement in ’physical summary score’ (MD 2.15, 95% CI 1.26 to 3.04, P = 0.02, 5 trials,
429 participants, moderate-quality evidence) and in ’mental summary score’ (MD 3.76, 95% CI 2.70 to 4.82, P < 0.01, 4 trials,
343 participants, moderate-quality evidence) secondary to exercise. Two trials reported the remaining domains of the SF-36. Data
showed improvements secondary to exercise in ’physical function’ and ’general health’. The other domains - ’role physical’, ’bodily
pain’, ’vitality’, ’social’, ’role emotional’, and ’mental health’ - did not show improvement at six months.
Evidence was generally limited in trials comparing exercise versus antiplatelet therapy, pentoxifylline, iloprost, vitamin E, and pneumatic
foot and calf compression owing to small numbers of trials and participants.
Review authors used GRADE to assess the evidence presented in this review and determined that quality was moderate to high.
Although results showed significant heterogeneity between trials, populations and outcomes were comparable overall, with findings
relevant to the claudicant population. Results were pooled for large sample sizes - over 300 participants for most outcomes - using
reproducible methods.
Authors’ conclusions
High-quality evidence shows that exercise programmes provided important benefit compared with placebo or usual care in improving
both pain-free and maximum walking distance in people with leg pain from IC who were considered to be fit for exercise intervention.
Exercise did not improve ABI, and we found no evidence of an effect of exercise on amputation or mortality. Exercise may improve
quality of life when compared with placebo or usual care. As time has progressed, the trials undertaken have begun to include exercise
versus exercise or other modalities; therefore we can include fewer of the new trials in this update.
P L A I N L A N G U A G E S U M M A R Y
Exercise for reducing intermittent claudication symptoms
Background
Intermittent claudication is a cramping leg pain that develops when walking and is relieved with rest. It is caused by inadequate blood
flow to the legmuscles caused by atherosclerosis (fatty deposits restricting blood flow through the arteries). People with mild tomoderate
claudication are advised to keep walking, stop smoking, and reduce cardiovascular risk factors. Other treatments include antiplatelet
therapy, pentoxifylline or cilostazol, angioplasty (inserting a balloon into the artery to open it up), and bypass surgery.
Studies and key results
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Review authors identified 32 controlled trials that randomised 1835 adults with stable leg pain to exercise, usual care or placebo, or
other interventions (current until November 2016). Researchers measured outcomes at times ranging from two weeks to two years.
Types of exercise varied from strength training to polestriding and upper or lower limb exercises; in general, supervised sessions were
held at least twice a week. The quality of included trials was moderate, mainly because of absence of relevant information. Ten trials
reported that in the exercise groups, pain-free walking distance and the maximum distance that participants could walk was increased.
Improvements were seen for up to two years. Exercise did not improve ankle to brachial blood pressure index. No evidence of an effect
of exercise was seen on death or need for amputation because data were limited. Researchers assessed quality of life using the SF-36
Questionnaire at three and six months. At three months, indicators of quality of life - ’physical function’, ’vitality’, and ’role physical’
- had all improved with exercise, but these data are limited, as only two trials reported this. Five studies reported improved ’physical
summary score’ and four studies reported improved ’mental health score’ following exercise at six months, with two trials also reporting
improvements in ’physical function’ and ’general health’. All other domains showed no improvement at six months following exercise.
Comparisons of exercise with antiplatelet therapy, pentoxifylline, iloprost, vitamin E, and pneumatic foot and calf compression were
limited because numbers of identified trials and participants were small.
Quality of the evidence
The present review shows that exercise programmes appear to improve walking distance for people considered fit for exercise regimens.
This benefit appears to be sustained over two years. Evidence presented in this review was of moderate to high quality. Although
differences between trials were evident, populations and outcomes were comparable overall, and findings were relevant to people with
intermittent claudication. Combined results were derived from large sample sizes - over 300 participants for most outcomes - using
reproducible methods.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Exercise compared with no exercise for intermittent claudication
Patient or population: adults with interm it tent claudicat ion
Settings: hospital or community-based physical therapy exercise programmes
Intervention: exercisea
Comparison: no exercise (previously known as usual care)
Outcomes Illustrative comparative risks* (95% CI)b Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No exercise Exercisea
Pain- free walking dis-
tance (m)
f ollow-up:
6 weeks to 24 months
Mean pain-f ree walking
distance ranged across
control groups f rom
63.3 m to 253 m.
Mean pain-f ree walk-
ing distance (m) in ex-
ercise groups ranged
f rom 116 m to 413
m. MD was 82.11 m
further in the exercise
group.
(95%CI 71.73 to 92.48)
391
(9 RCTs)
⊕⊕⊕⊕
highc
4/ 9 studies (Cucato
2013; Gardner 2002;
Jansen 1991 and Mika
2005) reported a clear
improvement.
Maximum walking dis-
tance (m)
f ollow-up:
6 weeks to 24 months
Mean maximum walk-
ing distance ranged
across control groups
f rom 122 m to 771 m
Mean maximum walk-
ing distance (m) in ex-
ercise groups ranged
f rom 136 m to 1100
m. MD was 120.36 m
further in the exercise
group.
(95% CI 50.79 to 189.
92)
500
(10 RCTs)
⊕⊕⊕⊕
highd
5/ 10 studies (Cucato
2013; Gardner 2002;
Jansen 1991; Tew
2015; Zwierska 2005)
reported a clear im-
provement.
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Ankle brachial index
f ollow-up:
3 to 12 months
Mean ABI ranged
across control groups
f rom 0.32 to 0.89.
Mean ABI in exercise
groups ranged f rom 0.
34 to 0.96. MD was 0.
04 higher in the exer-
cise group.
(95% CI 0.00 to 0.08)
570
(13 RCTs)
⊕⊕⊕©
moderatee
A change in ABI of 0.
04 is of lim ited clinical
signif icance.
Mortality: all-cause
deaths
follow-up: 3 to 12
months
A total of 9/ 273 deaths
occurred in the no exer-
cise group.
A total of 8/ 267 deaths
occurred in the exercise
group.
RR 0.92 (0.39 to 2.17) 540
(5 RCTs)
⊕⊕⊕©
moderatef
Amputation
f ollow-up: 12 months
A total of 2/ 88 amputa-
t ions occurred in the no
exercise group
No amputat ions oc-
curred in the exercise
group (0/ 89).
RR 0.20 (0.01 to 4.15) 177
(1 RCT)
⊕⊕©©
lowg
Quality of Life SF-36
Physical
Summary score (scale
0 to 100, higher score
indicates better quality
of lif e)
follow-up: 6 months
Mean physical sum-
mary score ranged
across control groups
f rom
34.2 to 47.1.
Mean Physical Sum-
mary score in exercise
groups ranged f rom 41
to 54.1. MD score was
2.15
higher in the exercise
group.
(95% CI 1.26 to 3.04)
429
(5 RCTs)
⊕⊕⊕©
moderateh
Quality of Life SF-36
Mental Summary score
(scale 0 to 100, higher
score indicates better
quality of lif e)
follow-up: 6 months
Mean Mental Summary
score ranged across
control groups f rom
38.8 to 62.0.
Mean Mental Sum-
mary score in exercise
groups ranged f rom 39.
6 to 67. MD score was
3.76
higher in the exercise
group.
(95% CI 2.7 to 4.82)
343
(4 RCTs)
⊕⊕⊕©
moderatei
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
ABI: ankle brachial index; CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SF: Short Form
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GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aVariability in type, durat ion, and f requency of exercise programmes as prescribed. Exercise programmes included a durat ion
of six weeks up to one year, generally twice or three t imes a week, varying in length between 30 minutes and one hour.
bWhen possible, the no exercise (control) groups results were measured at the same time point and were used in the meta-
analysis to calculate assumed risk.
cThe level of evidence was high, as most trials were of high quality.
dThe level of evidence was high, as most trials were of high quality. Heterogeneity was signif icant (P = 0.01, I2 = 89%), and
CIs were broad (50.79 to 189.92). However further research is unlikely to change this.
eWe downgraded by one step owing to signif icant heterogeneity (P ≤ 0.01, I2 = 64%); however CIs were narrow (0.00 to 0.09).
Given the size of the data set, it is unlikely that further data will demonstrate a dif ference between the two groups.
fWe downgraded the evidence by one step, as analysis included only f ive small studies (of which one was underpowered)
and showed wide conf idence intervals (imprecision).
gWe downgraded the evidence by two steps, as data are f rom a single study with wide CIs (imprecision) and events were few
overall.
hWe downgraded owing to heterogeneity (P = 0.02, I2 = 66%), narrow CI (1.26 to 3.04), and a symmetrical distribut ion on funnel
plot. Other quality of lif e measures were used and have been described more fully in the addit ional Table 1. Improvement was
also seen in the following domains: vitality and role physical at three months, physical funct ion, and general health at six
months.
iWe downgraded owing to heterogeneity (P < 0.01, I2 = 87%), narrow CI (2.70 to 4.82), and a symmetrical distribut ion on funnel
plot. Addit ional improvements in other domains may be seen in the future as more studies report their outcomes for quality
of lif e scores.
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B A C K G R O U N D
Peripheral arterial disease is an important cause of morbidity and
mortality for people inmanyWestern countries. It is estimated that
most adults have some degree of atherosclerosis by the time they
reachmiddle age, and approximately 4%will develop intermittent
claudication (Leng 1993). As the population ages, the prevalence
of claudication will increase. Risk factors for development of lower
limb arterial disease are similar to those for coronary heart disease,
and include smoking, raised cholesterol levels, hypertension, and
diabetes.
Several epidemiological studies have demonstrated an association
between sedentary habits, functional decline, and worsening clau-
dication (McDermott 2006;McDermott 2011). The impact of ex-
ercise therapy on physical functional ability, muscle strength, and
walking times has drawn increased focus since a review was pre-
pared in 2013 (Parmenter 2013). Over the past few years, further
research into calf muscle strength has supported known changes
in muscle architecture while enhancing focus on the impact of
these changes in relation to walking distance and physical func-
tion. Researchers have described reduction in myofibre cross-sec-
tional area, enzymes, and power (Clyne 1985; Dahllof 1974; King
2015; Koutakis 2015), along with alterations in gait (Gommans
2016; King 2012), among patients with intermittent claudication.
Description of the condition
Peripheral arterial disease covers a spectrum ranging from asymp-
tomatic disease through to claudication, critical limb ischaemia,
and finally limb loss. Within this spectrum, most people have rel-
atively stable disease, termed ’claudication’. Intermittent claudi-
cation occurs secondary to atherosclerosis of the lower limb arter-
ies, resulting from impaired blood flow. Whether at rest or when
walking slowly, this reduction may go unnoticed; however during
periods of exercise or walking with additional loads, for example,
carrying while shopping, a cycle of pain requiring short rests oc-
curs. This muscular, cramp-like tightening of the calf, the but-
tocks, or the foot on walking is known as ’claudication’.
Description of the intervention
Treatment options for intermittent claudication include bypass
surgery, angioplasty, and drug therapy, but the mainstay of treat-
ment for many patients with mild to moderate claudication re-
mains advice to ’stop smoking and keep walking’ (Housley 1988;
NCGC 2012) while modifying cardiovascular risk factors.
Exercise therapy or programmes usually require a regular weekly
commitment, lasting from six weeks to a year. In general, pro-
grammes are run twice or three times per week. Duration can vary;
usually a minimum of 30 minutes is required per session.
How the intervention might work
Researchers have conducted numerous studies of exercise therapy
using various regimens that differ in duration and intensity; many
of these studies suggest that exercise can prove beneficial for indi-
viduals with intermittent claudication (Ernst 1992). Underlying
mechanisms through which exercise may effect improvement in-
clude increased and more effective distribution of blood flow to
the legs (Ernst 1987a), improved rheological characteristics of the
blood (Ernst 1987), less reliance on anaerobic metabolism (Ruell
1984), and greater use of oxygen (Dahllof 1974).
A systematic review of the effect of exercise on lower limb haemo-
dynamics in individuals with mild to moderate claudication iden-
tified 33 trials. In these trials, investigators reported no change
when comparing effects of control versus exercise therapy on rest-
ing ankle brachial index (ABI), postexercise ABI, resting calf ar-
terial blood flow, reactive hyperaemic blood flow post ischaemia,
and resting toe systolic pressure (Parmenter 2011). An extensive
non-systematic review of the literature focussed on exercise train-
ing in people with claudication and physiological changes associ-
ated with exercise (Haas 2012). This review discussed how regular
exercise improves endothelial flow-mediated dilatation (FMD).
Exercise training also improves FMD in those with claudication.
Exercise is proposed to improve walking among claudicants
through angiogenesis. Underlying biomechanisms by which this
may occur include ischaemia, sheer stress secondary to exercise,
and remodelling of skeletal muscle (Hiatt 1994; Regensteiner
1993). Researchers have done extensive work on the changes that
occur in skeletal muscle secondary to claudication. These changes
can be summarised as a change in capillary density (Clyne 1985),
as a ratio of type I to type II fibres (Clyne 1985; Hiatt 1994;
Sjöström 1982), or as increases in arteriogenesis and mitochon-
drial activity. Trialists have described subsequent changes in skele-
tal muscle that can occur with training in humans (Lundgren
1989a; Terjung 1988; Wang 2009), as well as in animal models
with artificial hindlimb stenoses (Yang 1991).
More recently, researchers have explored changes secondary to dif-
fering exercise programmes, while focussing on calpain activity,
which has been associated with muscle atrophy in animal models.
When trial authors explored effects of walking regimens versus
strength training combined with walking, they noted that neither
was seen to alter calpain activity (Delaney 2014).
The impact of peripheral arterial disease (PAD) on lower limb
skeletal muscle becomes apparent when focussing on daily tasks
or measuring strength. Individuals with PAD have reduced lower
limb strength and ability or endurance for performing lower limb
tasks, that is, knee flexion, dorsiflexion, or plantar flexion, when
compared with healthy controls (Câmara 2012). In addition, peo-
ple with PAD and reduced muscle density are more likely to have
higher all-cause and cardiovascular disease mortality (McDermott
2012).
Clinicians have identified reducedmuscle strength (Câmara 2012;
Gohil 2013a; Parmenter 2013a), decreased walking distances
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(Parmenter 2013a), greater imbalance (Gohil 2013; Mockford
2014), and alterations in gait (King 2012; Koutakis 2010), sec-
ondary to PAD.
Why it is important to do this review
A meta-analysis of exercise rehabilitation programmes for claudi-
cation pain showed that exercise training to near-maximal pain
for at least six months was beneficial in improving claudication
(Gardner 1995). That review provided good evidence for the best
type of exercise therapy but did not compare findings with non-
exercised control groups. The present Cochrane review focusses
on randomised controlled trials only and encompasses additional
endpoints. The National Institute for Health and Care Excel-
lence (NICE) (NCGC 2012) currently advocates that all patients
with PAD should undergo an exercise programme as first-line
treatment. Numerous other studies have echoed this advice (Haas
2012; Lauret 2012;Willigendael 2005). However, uptake remains
low across the UK. This review aims to add weight to the current
body of available evidence recommending exercise, while demon-
strating effects of different durations of exercise on walking dis-
tance and quality of life.
O B J E C T I V E S
Our goal was to determine whether an exercise programme was
effective in alleviating symptoms and increasing walking treadmill
distances and walking times in people with intermittent claudica-
tion. Secondary objectives were to determine whether exercise was
effective in preventing deterioration of underlying disease, reduc-
ing cardiovascular events and improving quality of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) of an exercise
regimen versus control, or versus medical therapy. We excluded
trials that used alternation (e.g. allocation by date of birth or days
of the week).We included trials that did not perform intention-to-
treat analysis, provided all randomised participantswere accounted
for.We excluded trials for which numerical data were not available
in a usable format, despite contact with study authors, but that
were otherwise suitable.
We included studies in this review if they focussed on exercise ver-
sus usual care or other medical interventions. We excluded stud-
ies focussing on exercise compared with other forms of exercise,
unsupervised exercise, angioplasty, or surgery, to prevent over-
lap with other Cochrane reviews (Antoniou 2017; Fakhry 2013;
Fokkenrood 2013; Fowkes 1998). We excluded studies in which
usual care included walking advice or suggestions to increase daily
exercise, as this advice constitutes unsupervised exercise. Although
the exclusion of walking advice as part of usual caremay be deemed
controversial, this has been undertaken according to what has been
reported by the trialists in the study papers.
Types of participants
We included trials involving participants with symptomatic inter-
mittent claudication due to atherosclerotic disease. Intermittent
claudication may be diagnosed objectively by an ABI < 0.9 or evi-
dence of PAD on Doppler ultrasound or angiography, or both, or
by questionnaire or clinically if objective measures such as ABI or
imaging were not used or reported. We excluded studies of par-
ticipants with asymptomatic lower limb atherosclerosis that was
identified by testing.
Types of interventions
We included any exercise programme used for treatment of pa-
tients with intermittent claudication, such as walking, skipping,
and running, and home-based therapies provided researchers com-
pared treatment against placebo or no therapy. Inclusion of trials
was not affected by duration, frequency, or intensity of the exercise
programme, but these issues were taken into account in the meta-
analysis. This review did not consider supervised versus unsuper-
vised exercise because this is the topic of another Cochrane review
(Fokkenrood 2013). Walking advice provided by consultants in
clinic can be seen as the best medical treatment or control. How-
ever, this may also be deemed unsupervised exercise. Therefore,
we excluded from this review all studies that provided best medical
treatment, which includes walking advice.
To avoid overlap with other Cochrane reviews (Antoniou 2017;
Fakhry 2013; Fowkes 1998), this review excluded all modalities
by which exercise can be compared with percutaneous translumi-
nal angioplasty (PTA) or surgery. We therefore reviewed studies
originally included in this review comparing exercise versus PTA
or surgery, and excluded them when appropriate.
Types of outcome measures
We included only studies that reported one or more of the follow-
ing outcome measures: treadmill walking distance (time to onset
of pain or pain-free walking distance and maximum walking time
or maximum walking distance), ABI, quality of life, morbidity, or
amputation.
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Primary outcomes
• Treadmill walking distance (time to onset of pain or pain-
free walking distance and maximum walking time or maximum
walking distance)
Secondary outcomes
• ABI
• Mortality
• Amputation
• Quality of life (includes QoL measured by the Short Form
(SF)-36 Questionnaire and other validated measurements such as
the EuroQoL Group Quality of Life Questionnaire based on five
dimensions (EQ-5D), the Vascular Quality of Life Questionnaire
(VascuQol), and the Intermittent Claudication Questionnaire)
• Peak exercise blood flow
• Cardiovascular events
Search methods for identification of studies
Electronic searches
For this update, the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials.
• Cochrane Vascular Specialised Register (15 November
2016).
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 10) via the Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The CIS maintains the Cochrane Vascular Specialised Register,
which is constructed from weekly electronic searches of MED-
LINE Ovid, Embase, Ovid, the Cumulative Index to Nursing
and Allied Health Literature (CINAHL), and the Allied and
ComplementaryMedicineDatabase (AMED), and through hand-
searching of relevant journals. The full list of databases, jour-
nals, and conference proceedings searched, as well as the search
strategies used, is presented in the Specialised Register section
of the Cochrane Vascular Module in the Cochrane Library (
www.cochranelibrary.com).
The CIS searched the following trial registries for details of ongo-
ing and unpublished studies.
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch).
• ISRCTN Register (www.isrctn.com/).
See Appendix 2.
Searching other resources
We checked the reference lists of relevant studies retrieved via
electronic searches.
Data collection and analysis
Selection of studies
For this update, one of the review authors (RAL) independently
identified relevant trials and determined their eligibility for in-
clusion in the review; another review author (AH) checked this
work. We resolved disagreements by discussion or by consultation
with a third review author (GL); however this was not required.
As necessary, we sought additional information from authors of
all trials that appeared to meet the inclusion criteria.
Data extraction and management
Two review authors (RAL and AH) independently extracted data.
Review authors resolved disagreements by discussion and included
the final results in the review.
Assessment of risk of bias in included studies
For this update (2017), two review authors (RAL and AH) inde-
pendently performed risk of bias assessments. We discussed dis-
crepancies, and we planned that if we could not reach agreement,
we would ask a third review author (GL) to assess the trial. Risk
of bias assessment comprises seven domains: random sequence
generation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete outcome
data, selective reporting, and the additional option of assessing any
other aspects deemed to produce bias.
Measures of treatment effect
When appropriate, we pooled trial results in a statistical meta-anal-
ysis using guidelines published by Cochrane Vascular. We anal-
ysed continuous data by determiningmean differences (MDs) and
95% confidence intervals (CIs) using a fixed-effect model. When
significant heterogeneity was present, we used a random-effects
model. We analysed dichotomous data by determining risk ratios
(RRs) and 95% CIs using a fixed-effect model, unless we sus-
pected heterogeneity. In addition, for the primary outcome mea-
sure treadmill walking distance (time to onset of pain or pain-
free walking distance and maximum walking time or maximum
walking distance), we also analysed percentage change by using
the 95% CI.
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Unit of analysis issues
We analysed all data by using means and standard deviations.
When original study papers did not provide these, we calcu-
lated them using the method recommended by the statistician for
Cochrane Vascular. The unit of analysis was the individual partic-
ipant.
Dealing with missing data
When data were not available from the original study paper, we
contacted study authors to request the relevant data. If these were
not available, we excluded the paper from the review. If data for
at least one predefined outcome of the review were available, we
included the study and examined available data in the meta-anal-
ysis.
Assessment of heterogeneity
We subjectively tested heterogeneity between trial results by us-
ing clinical judgement of differences in patient populations, inter-
ventions (including type, duration, and intensity of exercise pro-
grammes), and outcome assessments. We assessed heterogeneity
statistically by using the Chi2 test and the I2 statistic. We deemed
heterogeneity as significant if the P value of the Chi2 test was less
than 0.01, or if I2 was greater than 70%. An I2 of 50% to 70%
equated to moderate heterogeneity.
Assessment of reporting biases
When we identified sufficient studies (> 10), we assessed publica-
tion bias using a funnel plot. For meta-analyses, when the num-
ber of studies was less than 10, we did not use funnel plots, as
this would have led to reduced power and inability to differentiate
artefactual from true asymmetry.
Data synthesis
For this update, two review authors (RAL and AH) independently
collected and pooled data, provided agreement was met. We then
uploaded data into Review Manager 5 (RevMan 2014) software
for analysis. We performed meta-analysis by using a fixed-effect
model unless we detected heterogeneity (Chi2 test P < 0.01); we
used a random-effects model in the analysis if heterogeneity was
present.
Subgroup analysis and investigation of heterogeneity
Owing to the numerous domains associated with assessment of
quality of life as per the Medical Outcomes Study (MOS) Short
Form (SF)-36, we analysed all domains by performing subgroup
analysis. When possible, we also analysed and presented data by
subgroups for usual care and placebo.
Sensitivity analysis
Exercise programmes consisted of 12-week interventions or 24-
week interventions. In one case, the duration of the programme
was two years. In view of the variable length of programmes, we
separated and analysed data as two separate analyses - one for 12
weeks and one for 24 weeks.
’Summary of findings’ table
For this update we included a table summarising the findings pre-
sented by this review for our main comparison of exercise versus
no exercise in adults with symptomatic intermittent claudication.
The study population continues to be at low risk with regards to
their claudication; however, this is only one aspect of a progressive
debilitating disease that can lead to limb loss and is accompanied
by the coexistent risk of cardiovascular disease. We selected for
inclusion in Summary of findings for the main comparison the
most important and clinically relevant outcomes thought to be
essential for decision-making. We described these under Types of
outcome measures; they include pain-free walking distance, max-
imum walking distance, ABI, mortality, amputation, and quality
of life. We calculated assumed control intervention risks by using
the mean number of events in control groups of selected studies
for each outcome. We used the system developed by the GRADE
Working Group in grading the quality of evidence as high, mod-
erate, low, or very low, on the basis of within-study risk of bias, di-
rectness of evidence, heterogeneity, precision of effects estimates,
and risk of publication bias (GRADE 2004).We usedGRADEpro
GDT (GRADEpro GDT 2015) software to create Summary of
findings for the main comparison.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
10Exercise for intermittent claudication (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
See Characteristics of included studies.
We included two additional trials for this update (McGuigan
2001; Tew 2015). We also included five publications related
to the previously included GOALS 2013 trial (McDermott
2013;McDermott 2013a; McDermott 2014; McDermott 2014a;
Rejeski 2014). However only one of these publications provided
data (on mortality at six months) that could be included within
the results section (McDermott 2014a). This brings the total
number of included studies to 32 (Arosio 2001; Castro-Sanchez
2013;Ciuffetti 1994;Collins 2005;Crowther 2012;Cucato 2013;
Dahllof 1974; Gardner 2002; Gelin 2001; GOALS 2013; Guidon
2010; Hiatt 1990; Hiatt 1994; Hobbs 2005; Jansen 1991; Kakkos
2005; Larsen 1966; Leicht 2011; Mannarino 1991; McDermott
2008; McGuigan 2001; Mika 2005; Mika 2006; Mika 2011;
Sanderson 2006; Schlager 2011; Tew 2009; Tew 2015; Tisi 1997;
Tsai 2002; Wood 2006; Zwierska 2005) and the total number of
participants to 1835.
Eighteen trials included fewer than 50 participants (Arosio 2001;
Ciuffetti 1994; Crowther 2012; Cucato 2013; Dahllof 1974;
Guidon 2010; Hiatt 1990; Hiatt 1994; Hobbs 2005; Jansen
1991; Kakkos 2005; Larsen 1966; Leicht 2011; Mannarino 1991;
McGuigan 2001; Sanderson 2006; Schlager 2011; Wood 2006),
ten between 50 and 100 participants (Castro-Sanchez 2013;
Collins 2005; Gardner 2002;Mika 2005;Mika 2006;Mika 2011;
Tew 2009; Tew 2015; Tisi 1997; Tsai 2002), three over 100 par-
ticipants (GOALS 2013; McDermott 2008; Zwierska 2005), and
one over 200 participants (Gelin 2001).
Researchers compared exercise versus six different modes of treat-
ment, the most common being usual care or placebo. Two early
trials compared exercise versus placebo tablets (Dahllof 1974;
Larsen 1966), but in more recent studies, trial authors used usual
care as the control comparator (Collins 2005; Crowther 2012;
Gardner 2002; Gelin 2001; GOALS 2013; Guidon 2010; Hiatt
1990; Hiatt 1994; Jansen 1991; Leicht 2011; McDermott 2008;
McGuigan 2001; Mika 2005; Mika 2006; Mika 2011; Sanderson
2006; Schlager 2011; Tew 2009; Tew 2015; Tisi 1997; Tsai 2002;
Wood 2006; Zwierska 2005). Investigators compared exercise
with the following drug therapies: antiplatelet agents (Mannarino
1991), pentoxifylline (Ciuffetti 1994), iloprost (Arosio 2001), and
vitamin E (Collins 2005). One study compared exercise versus
pneumatic foot and calf compression (Kakkos 2005); one used
a placebo treatment protocol of disconnected ultrasound elec-
trotherapy (Castro-Sanchez 2013); and one used a ’stretching class’
as usual care (Cucato 2013).
Inclusion and exclusion criteria of the included studies varied
widely, but usually excluded people with serious comorbidities
that would compromise an exercise programme, or would make
it impractical.
We noted some variation in the exercise regimens used, although
all recommended at least two sessions weekly. All specified some
element of supervision, except the earliest trial (Larsen 1966), in
which participants were simply advised to exercise at home and
were given some training or walking regimen. Types of exercise
varied from strength training to polestriding, cycling, and upper
or lower limb exercises. We did not identify studies that included
skipping or running. Duration of treatment generally fell within 3
to 12 months. Trialists measured outcomes at times ranging from
14 days to 2 years and reported variable compliance with exercise.
Nearly all trials used a treadmill walking test to assess one of the
outcome measures, but results show considerable variation in out-
comes. Some reported walking distance, and others reportedwalk-
ing times. Trial authors reported calf blood flow and ABI and often
provided haematological and biochemical measures. Trialists pro-
vided little information about mortality, amputations, and fatal or
non-fatal cardiovascular events. Eleven studies reported quality of
life measures (Collins 2005; Gardner 2002; Gelin 2001; GOALS
2013; Guidon 2010; Kakkos 2005; McDermott 2008; Tew 2015;
Tisi 1997; Tsai 2002; Zwierska 2005). As trials increasingly used
the Short Form (SF)-36 Questionnaire, we have combined these
results for meta-analysis in this review. We did not include in the
meta-analysis trials that used an alternative quality of life assess-
ment; we provided individual study findings in Table 1.
We sought additional information from trialists in most of the
included studies for the updated version of this review.
Excluded studies
See Characteristics of excluded studies.
For this update (2017), we excluded 18 additional studies (Aruna
2015; Cucato 2015; Dantas 2016; Gardner 2014;Gardner 2014a;
Gibbs 2013; Guidon 2013; Guirro 2015; Kono 2013; LIFE
Study; Mays 2015; NCT02075502; NCT02879019; PROPEL
study; Rodrigues 2014; Schlager 2011a; Sonaglia 2013; Ventura
1984). We added one publication to a previously excluded study
(EXITPAD 2010).
We excluded a total of 111 studies from the current review.
We excluded studies from this review because they compared
percutaneous transluminal angioplasty versus exercise (CLEVER
2009; Creasy 1990; Greenhalgh 2008; Hobbs 2006; Kruidenier
2011; Mazari 2010; Spronk 2009; SUPER study), surgery versus
exercise (Lundgren 1989), different exercise regimens (Allen 2010;
Andreozzi 2008; Beutel 1985; Buchwalsky 1974; Cachovan 1999;
Cheetham 2004; Choi 2012; Collins 2012; Cucato 2011; Cucato
2011a; Cucato 2015; Dedes 2010; Degischer 2002; Fakhry
2011; Gardner 2005; Gardner 2012; Gardner 2014; Gardner
2014a; Gottstein 1987; Jones 1996; Kiesewetter 1987; Labs 1999;
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Martinez 2009; Nawaz 1999; Nawaz 2001; NCT01241747;
NCT02879019;Nicolai 2010;Nielsen1977; Parr 2009; Patterson
1997; Pinto 1997; Riebe 2001; Ritti-Dias 2010; Rodrigues
2014; Saleem 2011; Savage 2001; Scheffler 1991; Slordahl 2005;
Sonaglia 2013; Thomson 1999; Zwierska 2004), and exercise
versus walking advice as the form of conservative best med-
ical treatment (Bronas 2011; Crowther 2008; EXERT 2009;
EXITPAD 2010; Gardner 2011; Gardner 2012; Hodges 2008;
Mays 2015; Nawaz 1999; NCT02075502; Nordanstig 2011; Parr
2009; Stewart 2008; Wang 2008). We excluded nine studies
because relevant suitable numerical data were not available de-
spite attempts to contact study authors (Collins 2010; Fowler
2002; Gibbellini 2000; Holm 1973; Maejima 2005; Schlager
2011a; Streminski 1992; Tebbutt 2011; Ventura 1984). We ex-
cluded the remainder of excluded studies because they did not
fit the inclusion criteria (e.g. participants did not have intermit-
tent claudication, not an RCT, insufficient evidence of randomly
allocated population, no non-exercise control group) (Aruna
2015; Brotons 2011; Bulling 1991; Carmeli 2004; Cina 1996;
Cunningham 2012; Dahllof 1976; Dantas 2016; Dittmar 1977;
Ericsson 1970; Ernst 1987; Ernst 1990; Fitzgerald 1971; Gibbs
2013; Guidon 2013; Guirro 2015; Kono 2013; Krause 1976;
Lee 2007; Leon 2005; Lepantalo 1984; LIFE Study; Mannarino
1988; Mannarino 1989; McDermott 2004; NCT01065740;
Necker 2003; Presern-Strukelj 200; PROPEL study; Riccioni
2010;Richardson 1991; Schoneberger 1994; Silvestro2002; Snabl
1958; Taft 2004; Treat-Jacobson 2012;Walker 2000;Waller 1988;
Wang 2008; Winterfeld 1983).
Ongoing studies
We included within the ongoing studies section two studies that
are still awaiting data: NCT01231360 (completed 2014) and
NCT01822457 (completed August 2016). See Characteristics of
ongoing studies.
Risk of bias in included studies
Figure 2 and Figure 3 provide an overall summary of bias present
within each of the included studies (see also Characteristics of
included studies). The high level of unclear bias was due to un-
clear reporting about sequence generation and allocation.We have
expanded upon these aspects below.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All studies were RCTs, but many reports provided no details
on random sequence generation other than a statement of ’ran-
domised’ (Arosio 2001; Crowther 2012; Cucato 2013; Dahllof
1974; Gardner 2002; Guidon 2010; Hiatt 1994; Jansen 1991;
Mannarino 1991;McGuigan 2001;Mika 2005;Mika 2006;Mika
2011; Tsai 2002; Wood 2006). See Figure 3. To ensure that all
trials were dealt with fairly, we deemed that any described as ’ran-
domised’ with no explanation as to how this was done had unclear
risk of bias. We deemed that the remaining studies were at low
risk of bias for random sequence generation.
A total of 15 studies did not report details of allocation con-
cealment (Arosio 2001; Cucato 2013; Dahllof 1974; Gardner
2002; Guidon 2010; Hiatt 1994; Jansen 1991; Mannarino 1991;
McGuigan 2001; Mika 2005; Mika 2006; Mika 2011; Tisi 1997;
Tsai 2002; Wood 2006); we deemed these studies to be at unclear
risk of selection bias. We deemed two studies to be at high risk of
bias because the randomisation procedure was not blinded (Hiatt
1990; Larsen 1966). The remaining studies provided details of
allocation concealment, and we judged them to be at low risk of
bias.
Blinding
As the nature of exercise-based studies involved an activity ver-
sus standard care, medication, or an intervention, review authors
deemed that blinding of participants was not possible. To ensure
that all trials used a standardised approach, we scored all as having
low risk of bias secondary to participant blinding. Inevitably in
trials of exercise, blinding was not possible; therefore significant
placebo responses may have occurred in trials comparing exercise
versus usual care.
Blinding of participants was not possible, and included trials have
additional risk of bias as outcome assessors may not be blinded to
the group to which a participant was randomised. Seven studies
did specify that outcome assessors were blinded; we judged these
to be at low risk of bias (Castro-Sanchez 2013; GOALS 2013;
McDermott 2008; Mika 2005; Mika 2011; Schlager 2011; Tsai
2002). For some, however, blinding involved a separate aspect of
the trial that was not focused on exercise, that is, vitamin E in
Collins 2005, or carnitine analysis in Hiatt 1990; we judged these
studies as having unclear risk. We deemed Dahllof 1974 to be at
high risk of bias because the outcome assessor was not blinded
to treatment groups. We judged the remainder of the included
studies to be at unclear risk of bias owing to lack of reporting on
blinding of outcome assessors.
Incomplete outcome data
Most trials reported no or minimal losses to follow-up (Arosio
2001; Castro-Sanchez 2013; Ciuffetti 1994; Collins 2005; Cucato
2013; Dahllof 1974; Gelin 2001; GOALS 2013; Hiatt 1994;
Hobbs 2005; Jansen 1991; Larsen 1966; Leicht 2011; Mannarino
1991; McDermott 2008; Mika 2005; Mika 2006; Mika 2011;
Sanderson 2006; Schlager 2011; Tew 2009; Tew 2015; Tsai 2002;
Wood 2006; Zwierska 2005). We judged studies that had an at-
trition rate of 20% or more to be associated with higher risk of
bias (Crowther 2012; Gardner 2002; Guidon 2010; Hiatt 1990;
Kakkos 2005; McGuigan 2001; Tisi 1997).
We judged five studies to be at unclear risk of bias (Arosio 2001;
Cucato 2013; Dahllof 1974; Jansen 1991; Mannarino 1991);
Arosio 2001, Dahllof 1974, Jansen 1991, and Mannarino 1991
because investigators did not mention whether all enrolled par-
ticipants completed the studies, and Cucato 2013 because only
participants from the exercise group were lost to follow-up.
Selective reporting
All studies reported their prespecified outcome measures and were
at low risk of reporting bias. Guidon 2010 discussed results of
theWalking Impairment Questionnaire (WIQ) and the Intermit-
tent Claudication Questionnaire (ICQ) for 30 of 44 randomised
participants; therefore, we judged this study to be at high risk
of selective reporting bias. Castro-Sanchez 2013 did not report
on intermittent claudication distance; we therefore classified it as
having high risk. Hiatt 1990 did not specifically report on max-
imum walking distance or intermittent claudication in the treat-
ment group but correlated it with treadmill performance; there-
fore, we classified this study as having high risk of reporting bias.
Other potential sources of bias
We initially labelled studies as having high risk of bias when they
failed to meet sample size calculations (Kakkos 2005; McDermott
2008; McGuigan 2001). Kakkos 2005 reported an attrition rate
of 26% (8 of 34 discontinued); we therefore kept it at high risk.
However, we reclassified McDermott 2008 to unclear risk of bias,
as the attrition rate was low; according to power calculations, 50
were needed in each group, and 50 completed the supervised ex-
ercise therapy (SET) whilst 48 in the control group completed the
study. We also reclassified McGuigan 2001 to unclear risk of bias
as the reported attrition rate was low.
Reporting of treatment group numbers varied in the results section
of Crowther 2012; effects on outcomes were unclear. We therefore
judged the study to be at high risk of bias.
Eleven studies were at low risk of bias (Castro-Sanchez 2013;
Collins 2005; Gardner 2002; Jansen 1991; Mika 2005; Mika
2011; Sanderson 2006; Schlager 2011; Tisi 1997; Tsai 2002;
Zwierska 2005).
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Eleven studies included small sample sizes; we therefore deemed
these studies to be at unclear risk of bias (Arosio 2001; Ciuffetti
1994;Cucato 2013;Dahllof 1974;Hiatt 1990;Hiatt 1994;Hobbs
2005; Larsen 1966; Leicht 2011; Mannarino 1991; Wood 2006).
We deemed the remaining six studies to be at unclear risk of bias
for a variety of other reasons (Gelin 2001; GOALS 2013; Guidon
2010; Mika 2006; Tew 2009; Tew 2015). Please see the risk of
bias tables for additional details.
Effects of interventions
See: Summary of findings for the main comparison Is exercise
an effective intervention in intermittent claudication?
Exercise regimen compared with placebo or usual
care
Overall outcomes
The wide range of reported time points meant that the overall
analysis includes the last data time point at which data were pre-
sented in the study publications. This section shows a high degree
of heterogeneity, with low heterogeneity noted in Analysis 1.2 and
Analysis 1.8.
Maximum walking distance
(Analysis 1.1)
Ten trials with 500 participants reported this outcome and showed
significant statistical heterogeneity (I2 = 89%, P < 0.00001) there-
forewe used a random-effectsmodel (Cucato 2013;Gardner 2002;
Gelin 2001; Hobbs 2005; Jansen 1991; Leicht 2011; Schlager
2011; Tew 2009; Tew 2015; Zwierska 2005). The exercise group
showed overall improvement in maximum walking distance (MD
120.36 metres, 95% CI 50.79 to 189.92, P < 0.00007, high qual-
ity of evidence as assessed via GRADE).
Pain-free walking distance
(Analysis 1.2)
Nine trials with a total of 391 participants reported on this out-
come (Cucato 2013; Gardner 2002; Hobbs 2005; Jansen 1991;
Leicht 2011; Mika 2005; Tew 2009; Tew 2015; Zwierska 2005)
and noted improvement in pain-free walking distance in the ex-
ercise group (MD 82.11 metres, 95% CI 71.73 to 92.48, P <
0.00001, low quality of evidence as assessed via GRADE). Trials
showed no significant heterogeneity (I2 = 41%, P = 0.1) therefore
a fixed-effect model was used.
Maximum walking time
(Analysis 1.3)
Twelve studies with a total of 577 participants reported on maxi-
mumwalking time (Collins 2005; Crowther 2012; GOALS 2013;
Hiatt 1990; Hiatt 1994; Larsen 1966; McDermott 2008; Mika
2006;Mika 2011; Sanderson 2006; Tsai 2002;Wood 2006). Data
show overall improvement in walking time for those who un-
derwent exercise (MD 4.51 minutes, 95% CI 3.11 to 5.92, P
< 0.00001, high-quality evidence). Heterogeneity between stud-
ies was found to be significant (I2 = 82%, P < 0.00001) there-
fore a random-effects model was used. Walking time improved in
eight trials (Crowther 2012; Hiatt 1990; Hiatt 1994; Larsen 1966;
McDermott 2008; Mika 2006; Mika 2011; Tsai 2002), which
demonstrated exercise to be effective.
Pain-free walking time
(Analysis 1.4)
Eleven studies with a total of 534 participants reported on pain-
free walking time (Collins 2005; Crowther 2012; GOALS 2013;
Hiatt 1994; Larsen 1966; McDermott 2008; Mika 2006; Mika
2011; Sanderson 2006; Tsai 2002; Wood 2006). Meta-analysis
demonstrated improvement in pain-free walking time for the exer-
cise groups (MD 2.93 minutes, 95% CI 1.77 to 4.09, P < 0.0001,
high-quality evidence). Heterogeneity between studies was found
to be significant (I2 = 89%, P < 0.00001) therefore a random-
effects model was used. Heterogeneity was most likely secondary
to differences in reporting times and variable length of exercise
programmes. Data show 100% improvement in pain-free walking
time, which was likely to be of clinical significance. Only two of
the studies found no real improvement with exercise (Sanderson
2006; Wood 2006).
Percentage change in maximum walking distance or time
(Analysis 1.5)
We calculated the percentage change in maximum walking dis-
tance or time for 15 studies with a total of 656 participants
(Arosio 2001; Crowther 2012; Cucato 2013; Gardner 2002;
GOALS 2013; Hiatt 1990; Hiatt 1994; Kakkos 2005; Leicht
2011;Mannarino 1991;McDermott 2008;Mika 2006;Tisi 1997;
Tsai 2002; Wood 2006). Meta-analysis reported overall improve-
ment in maximum walking distance or time for those who under-
went exercise (MD40.25%, 95%CI28.64 to 51.86, P <0.00001).
Heterogeneity between these studies was found to be significant
(P < 0.00001, I2 = 93%) therefore a random-effects model was
used.
Percentage change in pain-free walking distance
(intermittent claudication distance (ICD)) or time (ICT)
(Analysis 1.6)
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We calculated the percentage change in ICD or ICT for 15 stud-
ies with 703 participants (Arosio 2001; Collins 2005; Crowther
2012; Cucato 2013; Gardner 2002; GOALS 2013; Kakkos 2005;
Mannarino 1991; McDermott 2008; Mika 2005; Mika 2006;
Sanderson 2006; Tew 2009; Tsai 2002; Wood 2006). Results
showed overall improvement in percentage change for ICDor ICT
in favour of exercise (MD 58.42%, 95% CI 44.20 to 72.64, P <
0.00001). Heterogeneity between studies was found to be signif-
icant (P < 0.001, I2 = 70%) when a random-effects model was
used.
Ankle brachial index (ABI)
(Analysis 1.7)
Thirteen trials with a total of 570 participants reported this
outcome (Castro-Sanchez 2013; Collins 2005; Crowther 2012;
Gardner 2002; Gelin 2001;Hiatt 1990; Hiatt 1994; Hobbs 2005;
Leicht 2011; McGuigan 2001; Schlager 2011; Tew 2009; Tisi
1997). Meta-analysis showed a small change in ABI (MD 0.04,
95%CI 0.00 to 0.08, P = 0.06, moderate-quality evidence), which
was supported by three studies (Castro-Sanchez 2013; Crowther
2012; Schlager 2011). Studies showed significant statistical het-
erogeneity (P = 0.002, I2 = 63%) therefore a random-effects model
was used. Heterogeneity may be attributed to variations in exer-
cise programme type or duration. Of note, as the number of trials
included in updates has increased, the significance of change in
ABI with exercise has diminished to show no improvement.
Mortality
(Analysis 1.8)
Five studies with 540 participants reported on mortality (Gelin
2001; GOALS 2013; McDermott 2008; Schlager 2011; Tew
2009). Results show no differences in effect between groups (risk
ratio (RR) 0.92, 95% CI 0.39 to 2.17, P = 0.85, moderate-qual-
ity evidence). We updated these figures for this update, as recent
published data included mortality figures for GOALS 2013. We
noted no significant heterogeneity between trials (I 2 = 0%, P =
0.76).
Amputation
(Analysis 1.9)
Only Gelin 2001 reported on amputation. Two amputations oc-
curred in the usual care group, and none in the exercise group (RR
0.20, 95% CI 0.01 to 4.15, P = 0.3, low-quality evidence).
Quality of life
Overall, researchers reported quality of life (QoL) in numerous
different ways (see Table 1). SF-36 provided the only consistently
reported outcome for QoL, but this was reported at three and six
months, rather than at one year. We have reported below results
at these time points.
Other QoL questionnaires included the ICD Questionnaire (Tew
2015; Guidon 2010; Kakkos 2005), the Nottingham Health Pro-
file (NHP) (Tisi 1997), and the Intermittent Claudication-Spe-
cific Sickness Impact Profile (SIP) scale (SIPIC) (Gelin 2001).
Tew 2015 used the ICD Questionnaire to assess changes between
zero and six weeks. Data show no differences between intervention
and control groups in EQ-5D score at six weeks, but improvement
in ICD score in the intervention group (ICD score -10.6, 95%
CI -18.9 to - 2.3, P < 0.05) (see Table 1).
Cardiovascular events
None of the included studies reported on non-fatal cardiovascular
events. We have examined all-cause mortality in Analysis 1.8.
Peak exercise calf blood flow
(Analysis 1.10)
We included in the meta-analysis for this outcome four studies
with a total of 103 participants (Dahllof 1974; Gardner 2002;
Hiatt 1990; Larsen 1966). Results show no significant overall im-
provement in blood flow between groups (MD 0.94 mL/100 mL/
min, 95% CI -0.81 to 2.69, P = 0.29, low-quality evidence) (I
2 = 59%, P = 0.06, moderate heterogeneity between trials). We
downgraded the evidence owing to small sample size and wide
confidence intervals.
Three-monthly outcomes
Seven trials provided one or more outcomes at the three-month
time point for exercise compared with placebo or usual care (
Collins 2005;Hiatt 1990; Hiatt 1994;Mika 2011; Schlager 2011;
Tew 2009; Tsai 2002).
Maximum walking distance
(Analysis 2.1)
Three studies with 116 participants reported outcomes for max-
imum walking distance at the three-month time point (Cucato
2013; Schlager 2011; Tew 2009). Results showed no clear differ-
ences in distance between groups (MD 104.46 metres, 95% CI -
64.33 to 273.24, P = 0.23) along with significant heterogeneity (P
= 0.008, I2 = 79%) between studies when a random-effects model
was used.
Pain-free walking distance
(Analysis 2.2)
Three trials with 156 participants provided pain-free walking dis-
tance outcomes at three months (Cucato 2013; Mika 2005; Tew
2009).Data showed significant improvement in the exercise group
(MD 88.70 metres, 95% CI 58.25 to 119.15, P < 0.00001) (I2 =
16, P = 0.3, no significant heterogeneity).
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Maximum walking time
(Analysis 2.3)
Meta-analysis of five trials with 172 participants reporting max-
imum walking time at three months (Collins 2005; Hiatt 1990;
Hiatt 1994; Mika 2011; Tsai 2002) showed improvement with
exercise (MD 6.05 minutes, 95% CI 5.47 to 6.62, P < 0.00001)
and no significant heterogeneity (P = 0.62, I2 = 0%).
Pain-free walking time
(Analysis 2.4)
Three trials with 132 participants provided data on pain-free walk-
ing time at three months (Hiatt 1994; Mika 2011; Tsai 2002).
Meta-analysis demonstrated improvement in the exercise group
(MD 4.95 minutes, 95% CI 4.38 to 5.53, P < 0.00001) and sig-
nificant heterogeneity between trials (P = 0.02, I2 = 73%).
Ankle brachial index (ABI)
(Analysis 2.5)
Four studies with a total of 130 participants reported on ABI
outcomes at the three-month time point (Hiatt 1990; McGuigan
2001; Schlager 2011;Tew2009). In contrast to the overall analysis,
data show small differences in ABI between groups (MD 0.06,
95% CI 0.01 to 0.11, P = 0.02) (P = 0.06, I2 = 61%, moderate
heterogeneity).
Mortality
(Analysis 2.6)
Tew 2009 and GOALS 2013 reported on this outcome for a total
of 229 participants. No deaths occurred in either group inGOALS
2013, and Tew 2009 reported one death in the control group
compared with none in the exercise group (RR 0.30, 95% CI 0.01
to 6.98).
Quality of life
(Analysis 2.7)
Tsai 2002 and Guidon 2010 reported a quality of life analysis for
the SF-36 at three months. Domains found to improve secondary
to exercise included ’physical function’ (MD 6.60, 95% CI 2.37
to 10.83), ’vitality’ (MD 5.55, 95% CI 1.54 to 9.56), and ’role
physical’ (MD 10.31, 95% CI 3.64 to 16.98). A random-effects
model applied to assess for any variation revealed that the domain
’vitality’ continued to show improvement secondary to exercise,
but significance was lost for ’role physical’ (MD 16.06, 95% CI -
8.41 to 40.53) and ’physical function’ (MD 5.95, 95% CI-2.45
to 14.34).
Peak exercise calf blood flow
(Analysis 2.8)
Only Hiatt 1990 reported on this outcome at three months and
included 19 participants. Results show no clear differences be-
tween exercise and control groups at the end of the study (MD
2.50 mL/100 mL/min, 95% CI -1.49 to 6.49).
Six-monthly outcomes
Maximum walking distance
(Analysis 3.1)
Three studies with a total of 156 participants reported maximum
walking distance at six months (Gardner 2002; Schlager 2011;
Zwierska 2005). Results showed an increase in the exercise group
(MD 138.36 metres, 95% CI 22.39 to 254.34, P = 0.02) and
significant heterogeneity between studies (P = 0.002, I2 = 84%)
when a random-effects model was used.
Pain-free walking distance
(Analysis 3.2)
Two studies with 116 participants reported on pain-free walking
distance at six months (Gardner 2002; Zwierska 2005), noting
improvement in the exercise group (MD 52.14 metres, 95% CI
6.83 to 97.45, P = 0.02) (I2= 79%, P = 0.03, high heterogeneity).
Maximum walking time
(Analysis 3.3)
Four studies with a total of 295 participants reported outcomes for
maximum walking time at six months (Crowther 2012; GOALS
2013; Larsen 1966;McDermott 2008).Meta-analysis showed im-
provement in favour of exercise (MD 3.20 minutes, 95% CI 2.04
to 4.36, P < 0.00001) and high heterogeneity (P = 0.01, I2 = 72%).
Pain-free walking time
(Analysis 3.4)
Five trials with 292 participants provided pain-free walking time
outcomes at six months (Collins 2005; Crowther 2012; GOALS
2013; Larsen 1966; McDermott 2008), showing improvement
with exercise (MD 2.32 minutes, 95%CI 0.91 to 3.74, P < 0.001)
and significant heterogeneity between studies (P = 0.005, I2 =
73%) when a random-effects model was used.
Ankle brachial index (ABI)
(Analysis 3.5)
Six studies with 240 participants reported on ABI at six months
(Castro-Sanchez 2013; Collins 2005; Crowther 2012; Gardner
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2002; McGuigan 2001; Schlager 2011). Data showed no clear
differences in ABI between the two groups (MD 0.05, 95% CI -
0.01 to 0.11, P = 0.07) and significant heterogeneity (P = 0.007, I
2 = 69%) between studies when a random-effects model was used.
Mortality
(Analysis 3.6)
Only GOALS 2013 provided mortality data for the six-month
time point. Overall data show no clear difference in mortality
between exercise and non-exercise groups at the six-month time
period (RR 0.51, 95% CI 0.05 to 5.54, P = 0.58).
Quality of life
(Analysis 3.7)
Five studies with a total of 429 participants provided outcomes for
the SF-36 generic quality of life measure (Collins 2005; Gardner
2002; GOALS 2013; McDermott 2008; Zwierska 2005), which
showed improvement in quality of life secondary to exercise in cer-
tain domains, namely, ’physical summary score’ (MD 2.15, 95%
CI 1.26 to 3.04, P < 0.00001, moderate-quality evidence; sup-
ported with a random-effects model) and ’mental summary score’
(MD 3.76, 95% CI 2.70 to 4.82, P < 0.00001, 4 studies, 343 par-
ticipants,moderate-quality evidence). The ’mental summary score’
no longer showed improvement when a random-effects model was
applied (MD2.85, 95%CI -1.01 to -6.71).Heterogeneity was sig-
nificant (87%) for ’mental summary score’. Only two studies (43
participants) gave details on all domains; ’physical function’ (MD
9.78, 95% CI 0.82 to 18.74) and ’general health’ (MD 10.19,
95% CI 1.83 to 18.55) improved with exercise (Collins 2005;
Zwierska 2005); this was supported again when a random-effects
model was used. The other domains - ’role physical’, ’bodily pain’,
’vitality’, ’social function’, ’role emotional’, and ’mental health’ -
did not show improvement.
Peak exercise calf blood flow
(Analysis 3.8)
Two studies with 66 participants reported on blood flow measure-
ments at six months (Gardner 2002; Larsen 1966). As with overall
and three-month analyses, six-month blood flow measurements
showed no differences between groups (MD 3.79 mL/100 mL/
min, 95% CI 0.51 to 7.07, P = 0.02). Results showed no signif-
icant heterogeneity (P = 0.33, I2 = 0%) between studies when a
fixed-effect model was used.
Publication bias
We assessed overall publication bias using a funnel plot in three
meta-analyses (Analysis 1.3; Analysis 1.4; Analysis 1.7) (see Figure
4; Figure 5; and Figure 6).
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Figure 4. Funnel plot of comparison: 1 Overall outcomes: exercise regimen compared with placebo or usual
care, outcome: 1.1 Maximum walking time (min).
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Figure 5. Funnel plot of comparison: 1 Overall outcomes: exercise regimen compared with placebo or usual
care, outcome: 1.4 Pain-free walking time (min).
21Exercise for intermittent claudication (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 6. Funnel plot of comparison: 1 Overall outcomes: Exercise regimen compared with placebo or
usual care, outcome: 1.5 Ankle brachial index.
The funnel plot in Figure 4 shows that 10 studies were within
the 95% CI, and two were outside this range. Overall plot data
were symmetrical, suggesting no evidence of publication bias or
asymmetry secondary to the presence of smaller studies.
The funnel plot in Figure 5 indicates that seven studies were within
the 95% CI, and three were outside this range. Overall plot data
were asymmetrical, suggesting bias, possibly attributed to the pres-
ence of smaller studies.
The funnel plot in Figure 6 revealed that nine studies were within
the 95% CI, and three were outside this range. Overall plot data
were asymmetrical, suggesting bias, possibly attributed to the pres-
ence of smaller studies.
Exercise regimen compared with antiplatelet therapy
One trial involving 10 participants compared exercise with an-
tiplatelet therapy (Mannarino 1991) and reported the following
results.
Maximum walking time
(Analysis 4.1)
After six months of treatment, maximum walking time was im-
proved in the exercise group compared with the group treated with
antiplatelet therapy (MD 1.06 minutes, 95% CI 0.15 to 1.97).
Maximum walking time was increased by 86% in the exercise
group and by 38% in antiplatelet therapy group.
Ankle brachial index (ABI)
(Analysis 4.2)
Results show no differences between exercise and antiplatelet ther-
apy groups at the end of the trial (MD 0.00, 95% CI -0.22 to
0.22).
Peak exercise calf blood flow
(Analysis 4.3)
Results show no clear differences in calf blood flow between an-
tiplatelet therapy and exercise groups after six months, although
flow tended to be higher in the exercise group (MD 2.18 mL/100
mL/min, 95% CI -0.28 to 4.64).
Mannarino 1991 did not report the remaining outcomes of this
review.
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Exercise regimen compared with pentoxifylline
One trial involving 30 participants compared exercise versus pen-
toxifylline (Ciuffetti 1994) and reported the following results.
Maximum walking time
(Analysis 5.1)
After 13 weeks of therapy, maximum walking time was greater in
the pentoxifylline group than in the exercise group (MD -0.45
minutes, 95% CI -0.66 to -0.24). Walking distance increased by
62% in the exercise group and by 88% in pentoxifylline group.
Adverse events
Two participants experienced gastroenteritis during treatment
with pentoxifylline, but investigators did not consider this to be a
side effect of study treatments.
Ciuffetti 1994 did not report the remaining outcomes of this re-
view.
Exercise regimen compared with iloprost therapy
One study with 24 participants compared iloprost versus exercise
(Arosio 2001) and reported the following results.
Pain-free walking distance
(Analysis 6.2)
Data showed improvement in pain-free walking distance in the
exercise group at two weeks (MD 188.7 metres, 95% CI 15.38 to
362.02).
Maximum walking distance
(Analysis 6.1)
Data showed no clear effect on maximum walking distance in the
exercise group at two weeks (MD 196.80 metres, 95% CI -83.8
to 477.40).
Arosio 2001 did not report the remaining outcomes of this review.
Exercise regimen compared with pneumatic foot and
calf compression
One study with 25 participants compared exercise versus pneu-
matic foot and calf compression (Kakkos 2005).
Pain-free walking distance
(Analysis 7.2)
Data showed no clear effect on pain-free walking distance in the
pneumatic compression group compared with the exercise group
(MD -160.30 metres, 95% CI -438.88 to 118.28).
Maximum walking distance
(Analysis 7.1)
Data showed no clear effect on maximum walking distance in the
pneumatic compression group compared with the exercise group
(MD -61.90 metres, 95% CI -391.59 to 267.79).
Mortality
(Analysis 7.3)
One death occurredwithin the pneumatic calf compression group,
and no deaths occurred in the exercise group (odds ratio (OR)
3.52, 95% CI 0.13 to 95.09).
Kakkos 2005 did not report the remaining outcomes of this review.
Exercise regimen compared with vitamin E
One study involving 24 participants compared effects of vitamin
E and exercise (Collins 2005).
Maximum walking time
(Analysis 8.1; Analysis 8.2)
Collins 2005 demonstrated improvement secondary to exercise,
which was greater than with vitamin E alone, at three and six
months, respectively (MD 15.22 minutes, 95% CI 2.38 to 28.05;
MD 22.60 minutes, 95% CI 8.05 to 37.15).
Ankle brachial index (ABI)
(Analysis 8.3; Analysis 8.4)
ABI was unchanged at three and six months, respectively (MD -
0.03, 95% CI -0.21 to 0.15; MD 0.10, 95% CI -0.09 to 0.29).
Collins 2005 did not report the remaining outcomes of this review.
D I S C U S S I O N
Summary of main results
The data presented in this update generally confirm the findings
of previous versions of this review - that exercise has a significant
positive effect on walking times and walking distances in peo-
ple considered to be fit for exercise intervention, compared with
placebo or usual care. Although most studies examined outcomes
at three or six months, it is important to note that this benefit
would appear to be sustained for up to two years (Jansen 1991).
Of note, however, data show improvement in maximum walking
distance at six months but not at three months.
Mean improvements in walking distance and walking time with
exercisewere clinically and statistically significant; however inmost
cases, the data were not normally distributed. Some individuals
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responded with improvement of considerably larger magnitude
than the mean, whereas others responded less well, which may
reflect varying compliance with exercise programmes. Successful
programmes generally comprised physiotherapy with supervised
exercise two or three times per week for 30 to 60 minutes, of-
ten with walking, leg exercises, or treadmill training. Some pro-
grammes encouraged additional home exercise.
We used percentage change from baseline to allow a more holistic
understanding of change in walking ability. These additional pa-
rameters have demonstrated an increase in both initial claudica-
tion and maximum walking percentage changes, in keeping with
changes documented for initial claudication walking distance and
time, as well as for maximum walking distance and time. Of note,
use of combined data allowed inclusion of 15 studies and a larger
cohort of participants in the analysis.
Data related to ankle brachial index (ABI) and to other important
outcomes are sparse. Investigators provided no data on non-fatal
cardiovascular events and inconclusive data regarding mortality
and amputation.
Antiplatelet therapy was less effective than exercise in improving
walking distance and other measures of lower limb function, but
researchers presented no data pertaining to fatal and non-fatal
cardiovascular events. A previous meta-analysis has shown that
antiplatelet agents reduce the incidence of cardiovascular events
in people with claudication (Trialists 1994). Therefore, aspirin
should be of benefit despite lack of effect on the lower limb.
The single small trial comparing pentoxifylline with exercise
showed that participants on drug therapy had significantly longer
walking distances after three months than those on exercise ther-
apy (Ciuffetti 1994). Investigators reported no cardiovascular or
adverse events among those on pentoxifylline, but disadvantages
of drug treatmentmight include cost and lack of general cardiovas-
cular improvement. Arosio 2001 showed that exercise improved
pain-free walking time significantly more than iloprost, but this
was a small study (24 participants).
Pneumatic foot and calf compression showed no clear effect on
walking distances compared with exercise, again in a small trial
(Kakkos 2005). However, alternatives for improving blood flow
among those with poor mobility represent an important area
for future research in those who are unsuitable for exercise pro-
grammes. Therefore further research into such avenues may yield
more certain results and may therefore be of interest.
Researchers reported quality of life data on a range of scales, which
made it difficult to incorporate this information into a meta-anal-
ysis. Results were variable depending on the comparisons made;
this is a topic for future research.
Overall completeness and applicability of
evidence
Overall, it is not contested that exercise may provide benefit for
individuals with intermittent claudication. However, the overall
benefit and duration of exercise programmes differ. A standardised
approach with a minimum duration of six months appears to con-
fer benefit and would improve both pain-free andmaximumwalk-
ing distance. Review authors found scant data on the benefits of a
six-month programme compared with a three-month programme
when measured outcomes focused on quality of life, mortality, or
amputation risk. The general assumption is that exercise training
is safe in peripheral arterial disease, but the data presented are
often focussed on mortality and limb loss. Other cardiovascular
morbidity appears to be under-reported, and additional details on
safety data within exercise studies would be of value.
Criteria for participant selection resulted in exclusion of many
individuals with stable claudication for whom exercise was not
practical or safe owing to pre-existing medical conditions. As most
people with intermittent claudication are elderly, comorbidities
are common. For up to a third of people, exercise may not be a
suitable option. Other research trials and reviews have examined
optimummodes of exercise for people with intermittent claudica-
tion, for example, a Cochrane review explored supervised versus
unsupervised exercise for intermittent claudication (Fokkenrood
2013). The present review cannot resolve uncertainties about dif-
ferent exercise regimens.
This review did not investigate the issue of non-compliance, which
has a large impact on the use of supervised exercise classes and
how funding should be allocated for this treatment as advocated
by the National Institute for Health and Care Excellence (NICE)
(NCGC 2012). Further information on the cost-effectiveness of
exercise programmes is needed.
Quality of the evidence
We the review authors continue to believe that the quality of ev-
idence is high in supporting exercise as first-line treatment for
symptomatic claudicants. See Summary of findings for the main
comparison. In this review update, we have added only two studies
that support the body of literature already presented.
Compared with the previous version of this review, the evidence
presented has improved in quality, as reporting criteria have be-
come more stringent. In general, the bias present within papers
was often difficult to assess owing to absence of relevant informa-
tion. In these cases, we marked risk of bias as unclear, as evidence
on which to base a judgement was insufficient. Overall, included
studies were of moderate methodological quality.
Pooled outcomes for walking distance and maximum walking dis-
tance at all time points demonstrated significant heterogeneity.
This most likely was secondary to pooling of walking times from
some studies at two years and reporting of outcomes after three
months in other studies. When possible we addressed this hetero-
geneity by analysing data at specific time points, such as three and
six months post intervention. Regardless of this, data showed im-
provement in initial walking distance and time at three months,
and in maximum walking distance and time by six months.
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Publication bias remains an additional confounding factor for the
quality of evidence pooled within this review. Older studies have
been reported more poorly, as journal reporting criteria were pre-
viously less rigorous, resulting in greater inherent bias.
Potential biases in the review process
We searched the Specialised Register and the Cochrane Central
Register of Controlled Trials (CENTRAL) for new publications
about exercise in patients with intermittent claudication. Two re-
view authors independently assessed all new studies in keeping
with recommendations provided in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
The main cause of bias within this review is that walking advice
provided by consultants in clinics is now seen as the best medical
advice but may also be deemed as unsupervised exercise. Therefore
this review excluded all studies that reported best medical treat-
ment, which includes walking advice, as we believe this would
overlap with the Cochrane review on supervised versus unsuper-
vised exercise (Fokkenrood 2013). It remains possible that usual
care included walking advice, but this was not explicitly stated
by trialists in their study papers, suggesting one possible aspect of
reporting bias within studies.
It is the review authors’ feeling that as claudication research devel-
ops, a usual care non-exercise control group will cease to exist, as
its inclusion will be deemed unethical.
Finally, earlier studies used treadmill walking distance as the pri-
mary outcome measure, and this has continued to serve as a
method for assessment of improvement in claudication. Whilst
treadmill distances remain a reliable means of assessment, this
method is being superseded by other functional and subjective
assessments. Newer assessment tools to assess changes in walking
distance include GPS tracking, six-minute walks, subjective re-
porting, and assessments based on theWalking Impairment Ques-
tionnaire (WIQ). It is important that future reviews consider in-
clusion of these as outcome measures (Cucato 2013b; Tew 2013).
Agreements and disagreements with other
studies or reviews
This review is consistent with previous versions (Lane 2014; Leng
2000; Watson 2008) and adds to the body of available evidence
supporting exercise for people with intermittent claudication. This
evidence is also in line with NICE guidelines, which recommend
that exercise should be provided as first-line treatment for people
with intermittent claudication (NCGC 2012). Othermeta-analy-
ses such as Parmenter 2011 and other reviews such as Lauret 2012
and Lauret 2012a also support this finding.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides high-quality evidence showing that exercise
therapy should play an important part in the care of selected pa-
tients with intermittent claudication, to improve walking times
and distances. Effects were demonstrated following three months
of supervised exercise, although some programmes lasted longer
than one year. Limited data suggest that an effect is sustained for
up to two years. Exercise did not improve ankle brachial index
(ABI), and investigators detected no differences in the effect of
exercise between groups in terms of amputation or mortality. Ex-
ercise may improve quality of life when compared with placebo or
usual care.
Antiplatelet agents were less effective than exercise in improving
walking distance but should continue to be used because of bene-
fits in reducing cardiovascular events and death. In contrast, pen-
toxifylline was more effective than exercise but may have fewer
beneficial effects on the cardiovascular system in general. Iloprost
led to less improvement in walking time than exercise. Data show
no clear effect on walking distances when pneumatic foot and calf
compression was compared with exercise. However the number of
participants in these studies is small and data are limited.
Implications for research
Important questions involve the degree of supervision required in
any exercise regimen and how long any change in exercise habits
can be expected to last. Therefore, a trial with long follow-up -
of five years - is needed to compare the effectiveness of different
supervised and unsupervised regimens in terms of changing long-
term exercise patterns. Behavioural changes and attitudes towards
exercise have been items of key interest in areas such as cardiovas-
cular rehabilitation (Jolly 2009). More recent studies have demon-
strated that brief psychological interventions may play a key role
in improving walking distances among patients with intermittent
claudication up to one year (Cunningham 2012). A telling as-
pect of research into claudicants’ beliefs is their poor overall un-
derstanding of the disease and of why walking is recommended
(Cunningham 2014). Future holistic exercise programmes, which
may include cognitive-behavioural therapy and lifestyle and risk
factor modification, could provide great benefit in encouraging
people to start and maintain a better overall lifestyle.
Future research should also focus on compliance with exercise and
how this could be improved. Outcome measures should include
fatal and non-fatal cardiovascular events. In addition, expansion
of this review to assess the benefit of exercise for asymptomatic
patients and its impact on cardiovascularmorbidity is an important
goal.
Further cost-effectiveness analysis is required todeterminewhether
the cost of supervised sessions might offset the cost of deteriora-
tion in terms of surgery or occupation of in-patient beds for com-
plications such as myocardial infarction.
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A trial is needed to compare exercise treatment with pentoxifylline
to determine whether the benefit of drug treatment is sustained
over a longer period, and whether data show any differences in
cardiovascular events. Further investigation of pneumatic foot and
calf compression for treatment of individuals with intermittent
claudication is also needed. Consistency in use of quality of life
measures among different trials would be helpful in linking out-
comes to patient-assessed improvements.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arosio 2001
Methods Study design: RCT
Method of randomisation: ’randomly divided’
Exclusions post randomisation: not reported
Losses to follow-up: not reported
Participants Country: Italy
Setting: hospital
No. of participants: 24
Age: mean 65 years; 64.5 (55 to 69) years in exercise group; 66.4 (57 to 72) years in
iloprost group
Sex: all male
Inclusion criteria: Fontaine stage II PAD with IC during past 4 to 6 years, confirmed by
Doppler ultrasound, angiography, and ABI
Exclusion criteria: not clearly stated but inferred to be smoking, severe hypertension,
stroke, ischaemic attack, cerebrovascular disease, any drugs for PAD or other disease
except transdermal clonidine for mild to moderate hypertension
Interventions Intervention 1: physical exercise (n = 10) - walking, running, squat thrusts, 2 × day for
30 min, cycle ergometer for 30 min, plus 30 min constant load treadmill (2 mph, slope
0%)
Intervention 2: iloprost (0.5 to 2 ng/kg/min) (n = 10)
Duration: 14 days
Outcomes Endogenous NO products
Neutrophil adhesion
ICD (m) and ACD (m) from constant load treadmill test (2 mph, slope 0%)
Notes Exercise was interrupted at onset of pain, participant rested for 3 min, or until pain had
gone, then resumed activity until each 30-min block
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation method
provided. Simply stated, ’the groups were
randomly divided in two treatment regi-
mens’
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
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Arosio 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of whether all enrolled com-
pleted the study
Selective reporting (reporting bias) Low risk Prespecified outcome measures reported
Other bias Unclear risk Small numbers (n = 10 per treatment arm)
and duration for only 14 days
Castro-Sanchez 2013
Methods Study design: RCT
Method of randomisation: randomised balanced (stratified) selection process
Groups were balanced for type of medication received and Leriche-Fontaine stage (I
or IIa), via a stratification system that generates a sequence of letters (from a table of
correlatively ordered permutations) for each category and combination of categories
Exclusions post randomisation: 5; 3 in placebo (reasons: working hours, care for grand-
parents, and sprained ankle) and 2 in the physical therapy modality (reasons: terminally
ill husband, and bed rest)
Losses to follow-up: not reported
Participants Country: Spain
Setting: healthcare district
No. of participants: 68
Age: mean (SD) age, 53 (12) years; range, 41 to 65 years
Sex: 30 women and 38 men
Inclusion criteria: diagnosis of type 2 diabetes, postexercise ABI of 0.6 to 0.9, HbA1c of
7% to 13%, BMI of 25 to 40, and sedentary lifestyle
Exclusion criteria: other stages of PAD; peripheral venous insufficiency; cardiac, renal,
or hepatic insufficiency; a cardiovascular event in the previous year; arterial pressure >
160/90 mmHg; LDL cholesterol > 160 mg/dL; an active smoking habit (in 3 previous
years); and the presence of walking disorder, impaired skin integrity, or psychological or
neurological disorder
Interventions Intervention 1: Exercise group (n = 34) performed a session of 3 physical therapy modal-
ities 2 times/d at home
Intervention 2: Placebo group (n = 34) received a treatment protocol 1 day/week with
disconnected ultrasound electrotherapy equipment in dorsal and lumbar regions (15
minutes per region); these patients were instructed on the use of ultrasound equipment
and were unaware that it was switched off
Duration: 20 weeks
Outcomes Initial claudication walking distance (not reported in results); constant load treadmill
test (3 km/h, 10% grade)
Blood parameters: fibrinogen (mg/dL), haemoglobin (g/dL), glucose (mg/dL), choles-
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Castro-Sanchez 2013 (Continued)
terol (mg/dL), high-density lipoprotein (HDL) cholesterol (mg/dL), LDL cholesterol
(mg/dL), triglycerides (mg/dL), and HbA1c (%)
Doppler flow velocity
ABPI
Cardiovascular risk score
Heart rate during exercise test
Assessments at 3 time points: baseline (before treatments), immediately after the final
treatment session, and at 6 months after the conclusion of treatment
Notes Home exercise protocol described by Boutroux 1980
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised balanced (stratified) selection
process
Allocation concealment (selection bias) Low risk Groups were balanced for type of medi-
cation received and Leriche-Fontaine stage
(I or IIa) via a stratification system that
generates a sequence of letters (from a ta-
ble of correlatively ordered permutations)
for each category and combination of cat-
egories
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to the treatment
group.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Five dropouts were reported and excluded.
Selective reporting (reporting bias) High risk All outcomes stated - with the exception of
initial claudication walking distance
Other bias Low risk No evidence of other bias
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Ciuffetti 1994
Methods Study design: RCT
Method of randomisation: allocated by predetermined computer code. Not blinded
Exclusions post randomisation: not reported
Losses to follow-up: no dropouts reported
Participants Country: Italy
Setting: hospital
No. of participants: 30
Age: 48 to 64 years
Sex: male and female
Inclusion criteria: stable maximal walking time (90 to 130 s) at 2 previous 6-monthly
checks, plus stage II PAD confirmed by velocimetry and angiography
Exclusion criteria: no h/o vascular surgery, coronary or cerebrovascular disease, DM; no
factors affecting oxygen demand (e.g. anaemias); recent infection; treatment with va-
sodilators, antiplatelets, anticoagulants, or drugs affecting haemorrheological parameters
for previous 1 month
Interventions Treatment: 1 h exercise at home daily plus twice-weekly supervision as out-patients.
Home regimen: week 1, 500 m in 20 min; week 2, 1000 m in 40 min; week 3, 2000 m
in 60 min on the flat
Control: pentoxifylline 800 mg tds
Duration: 3 months
Outcomes Primary: treadmill test maximal walking distance (2 km/h on 12° slope)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by means of a predetermined
computer code
Allocation concealment (selection bias) Low risk Predetermined computer code
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Low risk All outcomes stated
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Ciuffetti 1994 (Continued)
Other bias Unclear risk n = 15 per group; small numbers; groups
matched for baseline gender and age
Collins 2005
Methods Study design: RCT
Method of randomisation: participants randomised after baseline testing completed; 4
groups, randomised 2 × 2 factorial analysis, permuted blocks: computer generated for
vit E, sealed envelopes for exercise
Exclusions post randomisation: none
Losses to follow-up: 6 (4 polestriding group, 2 control group)
Participants Country: USA
Setting: community
No. of participants: 52 (49 analysed)
Age: 65.8 ± 7.1 years polestriding group; 68.0 ± 8.6 control group
Sex: 51 M, 1 F
Inclusion criteria: history of IC, ABI < 0.95 at rest or < 0.85 after exercise, IC pain a
factor for arrested walking
Exclusion criteria: vascular surgery, angioplasty in previous 6 months; other comorbid
conditions that would interfere with participation in an exercise programme; currently
taking vit E, warfarin, or pentoxifylline; unable to give informed consent
Interventions Treatment: polestriding (n = 27), supervised training 3 times per week for 4 weeks, twice
weekly for 8 weeks, once weekly for 4 weeks, biweekly for 4 weeks, unsupervised for 4
weeks
Control: no exercise (n = 25), usual care. Seen biweekly for 3 months and monthly
thereafter
Duration: 24 weeks
Outcomes Primary: ABI, maximum walking distance, oxygen uptake
Secondary: health-related quality of life
Notes All participants given $6 travel for each visit and $5 for each test battery completed,
starting at $25
Secondary analysis of the 2 × 2 factorial design of Collins 2003; because results showed
no influence of vit E on exercise, researchers combined exercise groups and compared
findings with those of the non-exercise groups
The treadmill protocol began at a speed of 1.8 meter per hour (mph) and 0% grade.
After the first 6 minutes, speed increased by 0.2 mph every 3 minutes. Per cent grade
increased by 0.5% every 30 seconds
Risk of bias
Bias Authors’ judgement Support for judgement
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Collins 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Participants randomised after baseline test-
ing completed; 4 groups, randomised 2 ×
2 factorial analysis, permuted blocks, com-
puter generated
Allocation concealment (selection bias) Low risk Randomised 2 × 2 factorial analysis, per-
muted blocks, computer generated for vit
E. For exercise: sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded to tablets, but not to exercise
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessors blinded to serum vit E levels
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All outcomes stated
Other bias Low risk Controlled for additional visits by making
it fair across all 4 groups
Crowther 2012
Methods Study design: RCT
Method of randomisation: “randomly allocated using a blinded protocol”
Exclusions post randomisation: nil stated
Losses to follow-up: For personal reasons, 6 participants (n = 5 CPAD-IC, and n = 1
TPAD-IC) withdrew over the course of the research study
Participants Country: Australia
Setting: hospital
No. of participants: N = 22; control (CPAD-IC, n = 11) or treatment (TPAD-IC, n =
11) group
Age: CPAD-IC group: 67.1 (± 6.8), TPAD-IC group: 71.3 (± 8.5)
Sex: 50% male
Inclusion criteria: symptoms of IC, appropriate history of IC, imaging confirmation of
PAD on lower limb duplex or CTA, and ability and willingness to attend for regular
supervised exercise
Exclusion criteria: selection for surgical or endovascular intervention (n = 30), patient
preference (n = 20) and requirement for mobility aids, obvious gait abnormalities (e.g.
steppage, vaulting, circumduction, hip hiking), and medical conditions that influenced
gait (e.g. orthopaedic conditions, neurological impairment)
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Crowther 2012 (Continued)
Interventions Treatment: 6-month supervised exercise programme
Control: standard medical treatment as outlined in the Trans-Atlantic Inter-Society
Consensus (TASC II) guidelines
Duration: 6 months
Outcomes Primary: submaximal walking economy and walking performance during a graded tread-
mill exercise test
Secondary: body composition; resting ABI
Notes Exercise programme initially consisted of intermittent supervised treadmill walking 3
days per week for a total time of 25 minutes at 3.2 km/h (0.88 m/s). Participants were
required to walk until the pain level was perceived as 3 or 4 on theCPS. Exercise intensity
(via treadmill grade and walking speed) and duration (25 minutes up to a maximum of
40 minutes) were progressively increased once the participant could walk continuously
for 25 minutes at a level below 3 on the CPS. This exercise progression strategy was
continued over the 6-month period of the study
The graded treadmill walking protocol consisted of a constant speed of 3.2 km/h (0.88
m/s) at an incline of 0% for the first 2 min, which was then increased by 2% every 2
minutes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Description of randomisation limited to:
“Participants were randomly allocated us-
ing a blinded protocol”
Allocation concealment (selection bias) Low risk Blinded protocol; no further details pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 participants lost to follow-up. Groups left
uneven. However baseline data for the 2
groups were similar after participants who
dropped out were excluded
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk In Results section, numbers in CPAD and
TPAD groups alternate. In Table 1, CPAD
(n = 6), TPAD (n = 10); Table 2, CPAD (n
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= 10), TPAD (n = 6)
Cucato 2013
Methods Study design: RCT
Method of randomisation: randomised; nil else stated
Exclusions post randomisation: nil stated
Losses to follow-up: 4 from the walking group (reason: personal reasons)
Participants Country: Brazil
Setting: hospital
No. of participants: 29
Age: control 61 ± 8 years; walking training 64 ± 6 years
Sex: male
Inclusion criteria: Stable symptoms of ICwere recruited from a tertiary centre specialising
in vascular disease. Male patients with Fontaine stage II symptoms of IC for longer than
6 months, an ABI < 0.90 at rest in 1 or 2 legs, and who were able to walk for at least 2
min at 3.2 km/h on a treadmill were invited to participate
Exclusion criteria: obesity (BMI < 30 kg/m2); use of beta-blockers, non-dihydropyridine
calcium channel blockers, or peripheral vasodilators; inability to obtain the ABI; exercise
tolerance limited by factors other than claudication (i.e. arrhythmias, cardiac symptoms,
or exaggerated blood pressure rise); electrocardiogram response suggestive of myocardial
ischaemia, and h/o revascularisation in the previous year
Interventions Treatment: 15 × 2-min walking bouts, with 2-min intermittent rest periods. Exercise
intensity was adjusted to maintain heart rate within 4 bpm above or below the heart
rate of claudication pain onset (e.g. if the patient reported claudication pain onset in
the maximal treadmill test at 100 bpm, the heart rate exercise zone was set at 96 to 104
bpm). Treadmill speed was set at 3.2 km/h, while the grade was adjusted to achieve the
target heart rate
Twice-weekly 12-week walking exercise training programme
Control: stretching exercise classes
Duration: 12 weeks
Outcomes Primary: to analyse the pain, cardiovascular and metabolic responses experienced by
patients duringwalking exercise performed at the heart rate corresponding to claudication
pain onset, and to investigate the effects of a 12-week walking training programme at
this intensity on walking capacity in patients with IC
Secondary: to determine whether low-volume walking exercise training programme at
this intensity would induce walking performance improvements in this patient group
Graded treadmill test: PFWD, MWD
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Cucato 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised into 2 groups
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants given the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Participants from exercise group lost to fol-
low-up only. Baseline demographics be-
tween 2 groups matched in spite of attri-
tion
Selective reporting (reporting bias) Low risk All stated
Other bias Unclear risk Small numbers
Dahllof 1974
Methods Study design: RCT
Method of randomisation: states “randomised”. Not blinded
Exclusions post randomisation: not stated
Losses to follow-up: not stated
Participants Country: Sweden
Setting: not stated
No. of participants: 18
Age: 54 to 71 years
Sex: male and female
Inclusion criteria: IC for > 1 year
Exclusion criteria: DM or IHD
Interventions Treatment: 30-min training sessions 3 times weekly, supervised by a physiotherapist,
including dynamic leg exercises beyond the appearance of pain
Control: placebo tablets
Duration: 6 months
Outcomes Primary: treadmill test pain-free and maximal walking distance (max 1000 m), at 4 km/
h
Secondary: calf blood flow - venous occlusion plethysmography after ischaemic foot
exercises
Notes
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Dahllof 1974 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, nil else reported
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded to tablets, but not to exercise
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Physiotherapist ran exercise aspect.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of whether all enrolled com-
pleted the study
Selective reporting (reporting bias) Low risk All outcomes stated
Other bias Unclear risk Small numbers (n = 18)
Gardner 2002
Methods Study design: RCT
Method of randomisation: not described
Exclusions post randomisation: nil
Losses to follow-up: 3 in treatment group, 6 in control group dropped out. More at 18
months. 31 remained
Participants Country: USA
Setting: vascular clinics, newspaper and radio adverts
No. of participants: 61 originally, 31 remained at 18 months
Age: over 60 years
Sex: 90% male
Inclusion criteria: Fontaine II PAD Rose Questionnaire. ABI < 0.97 at rest. IC limiting
factor on treadmill
Exclusion criteria: other significantmedical conditions limiting exercise tolerance, poorly
controlled DM
Interventions Treatment: 30-min training sessions 3 times weekly for 6 months, then twice weekly for
12 months
Control: usual care
Duration: 6 months and 18 months
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Gardner 2002 (Continued)
Outcomes Treadmill distance to claudication
Maximum claudication distance
ABI
Peak oxygen uptake
Walking economy
Six-minute walking test distance
Accelerometer-derived physical activity
Walking Impairment Questionnaire
Calf blood flow
Health-related quality of life on SF-36
Self-perceived ambulatory measures
Notes Participants performed a progressive, graded treadmill protocol (2 mph, 0% grade with
2% increase every 2 minutes) until maximal claudication pain. Distance walked to onset
of claudication pain, distance walked to maximal claudication pain, time to relief of
claudication pain after the test, and peak oxygen uptake were measured
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation not specified
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants given the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers for attrition provided for all out-
comes except the HRQoL, but reasons not
stated
61 originally, 31 remained at 18 months:
high loss to follow-up
Selective reporting (reporting bias) Low risk All prespecified outcomes reported on
Other bias Low risk No evidence of other bias
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Gelin 2001
Methods Study design: RCT
Method of randomisation: block, computer
Exclusions post randomisation: nil stated
Losses to follow-up: 39 (13 control, 15 training, 11 invasive therapy) did not complete
evaluation at 1 year. A total of 90 patients did not complete treatment as allocated,
although analysis was based on intention to treat. 15 were unsuitable for surgery and 17
received angioplasty in surgery arm. 25 withdrew from quality of life section
Participants Country: Sweden
Setting: vascular out-patients
No. of participants: 253
Age: mean 67 (range 45 to 81) years
Sex: 67% male
Inclusion criteria: stable IC for > 6 months, ABI < 0.6 Maximum postischaemic blood
flow < 25 mL/min/100 g, willing to undergo operations
Exclusion criteria: contraindication to surgery; other disorder limiting treadmill walking
Interventions Treatment:
• Supervised exercise training 30 min 3 times per week for 6 months, then 6 to 12
months 2 sessions per week
• Invasive surgery/endovascular procedure, based on angiographic findings
Control: observation only
Duration: 1 year
Outcomes Primary: mortality, ABI, amputation, treadmill distance; max postischaemic calf blood
flow, big toe systolic pressure
Secondary: blood pressure, haemoglobin, cholesterol, triglycerides, creatine, quality of
life
Notes Quality of life (data for 171 only, 18 changed group but were analysed in original)
Randomised before pretreatment investigations. Low compliance in exercise group but
classes offered for longer than most studies
Results for ABI omitted standard deviations.
Walking test was performed on a treadmill with a progressively inclinating slope from
0° to 12°, simulating a gradually increasing workload
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised into 3 groups ’utilising a com-
puter based algorithm, taking 21 assumed
long-term prognostic variables into ac-
count’
Allocation concealment (selection bias) Low risk Randomisation performed by an indepen-
dent nurse, who communicated the alloca-
tion group to the responsible physician
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk No competing interests declared. Funding
transparent. High number of cross-overs
described and discussed. However, greater
degree of treatment dropouts in the exer-
cise group; total numbers for this section
(58%); has the potential to bias reported
outcomes (PTA/surgery 80%)
GOALS 2013
Methods Study design: RCT
Method of randomisation: parallel-design randomised controlled clinical trial
Exclusions post randomisation: 5 lost interest (control), 8 lost interest in exercise group
Losses to follow-up: in CONSORT diagram; 3 deaths overall
Participants Country: USA
Setting: community
No. of participants: 194
Age: 69.3 (9.5) exercise group; 71.0 (9.6) control group
Sex: 49 (50.5%) men in exercise group; 48 (49.5%) in control group
Inclusion criteria: ABI ≤ 0.90 in either leg. Individuals with a resting ABI ≥ 0.91
to ≤ 1.00 at baseline were eligible if their ABI dropped by at least 20% after a heel-
rise test. Individuals with a resting ABI > 0.90 were eligible if they provided medical
record documentation of lower extremity revascularisation or evidence of PAD from an
accredited vascular laboratory
Exclusion criteria: potential participants with a below- or above-knee amputation;
wheelchair confinement; inability to walk at least 50 feet without stopping; use of a
walking aid other than a cane; inability to attend weekly sessions; walking impairment
for a reason other than PAD, foot ulcer, or critical limb ischaemia; significant visual or
hearing impairment; non-completion of the study run-in (attendance at 2 weekly health
education sessions over a 3-week period); major surgery or lower extremity revascularisa-
tion during the previous 3months or planned during the next 12 months; major medical
illness including cancer treatment during the prior 12 months; current participation in
another clinical trial or in another exercise trial within the past 3 months; completion of
cardiac rehabilitation during the past 3 months; Parkinson disease; requirement
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of oxygen with activity or exercise; determination that exercise may be unsafe including
having more than a class II New York Heart Association level of heart failure or angina;
an increase in angina pectoris during the prior 6 months; an abnormal baseline exercise
stress test; an exercise level similar to that targeted in the intervention at the time of
recruitment; and a Mini-Mental State Examination score of < 23 at baseline
Interventions Treatment: Our intervention applied principles from social cognitive theory, the group
dynamics literature, and research on self-regulation to motivate participants to adhere
to home-based walking exercise. Participants met once weekly for 90 minutes in a group
with other PAD participants for the entire 6 months of the intervention. Forty-five
minutes was devoted to facilitator-led discussions and 45 minutes to walking around an
indoor track
Control: The health education control group attended weekly 60-minute group sessions
with other PAD participants. Physicians and other healthcare professionals provided
lectures on topics including managing hypertension, cancer screening, and vaccinations
Control group attended weekly lectures about topics not related to exercise.
Duration: 6 months
Outcomes Primary: 6-minute walk test
Secondary: maximal treadmill walking time, pain-free treadmill walking time, physical
activity, Walking Impairment Questionnaire (WIQ) scores, and Physical Health Com-
posite Score (PCS) and Mental Health Composite Score (MCS) from the 12-item Med-
ical Outcomes Study Short-Form Health Survey (SF-12)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk RCT: parallel-design randomised con-
trolled clinical trial randomised by com-
puter via a randomly permuted block
method
Allocation concealment (selection bias) Low risk Eligible participants were randomised by
computer via a randomly permuted block
method, stratifying by baseline 6-minute
walk performance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcomes were measured before ran-
domisation and at 6-month follow-up by
assessors unaware of participants’ group as-
signment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up rates were 90.7% and 92.8% in
the intervention and control groups. After
exclusion of 3 participants who died before
follow-up testing, follow-up rates were 91.
7% and 94.7%
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Multiple imputation was used by study
authors to account for missing data at
6-month follow-up, including additional
analyses in which a value of zero was as-
signed for missing 6-month follow-up data
for decedents
Guidon 2010
Methods Study design: RCT
Method of randomisation: “randomly allocated”
Exclusions post randomisation: nil stated
Losses to follow-up: 13 withdrew before follow-up
Participants Country: Ireland
Setting: not stated
No. of participants: 44 initially randomised, 30 completed study
Age: 67 ± 8.12 years
Sex: 70.5% male
Inclusion criteria: IC with ABI < 0.9
Exclusion criteria: nil stated
Interventions Treatment: twice-weekly supervised exercise programme for 12 weeks
Control: usual care
Duration: 12 weeks
Outcomes Walking Impairment Questionnaire
Intermittent Claudication Questionnaire
SF-36
Notes RCT performed by School of Physiotherapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”; no further informa-
tion available
Allocation concealment (selection bias) Unclear risk Not stated
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 25% lost to follow-up
Selective reporting (reporting bias) High risk Only WIQ and ICQ discussed for 30/44
participants
Other bias Unclear risk RCT performed by School of Physiother-
apy: who will require funding and may
therefore be undertaking the study to pro-
vide weight for sustaining or undertaking
additional classes
Hiatt 1990
Methods Study design: RCT
Method of randomisation: randomised in pairs by coin toss
Exclusions post randomisation: 6 were discontinued from the study. 4 treated partic-
ipants were discontinued: 3 for non-compliance with exercise training sessions and 1
for development of medical problems unrelated to PAD. Two control participants were
discontinued: 1 for medical problems not due to PAD and the second for progression
of arterial disease, as previously defined
Losses to follow-up: nil
Participants Country: USA
Setting: not stated
No. of participants: 19 (25 enrolled, 6 discontinued); 10 treatment and 9 control
Age: mean 61 years (treatment), 59 years (control)
Sex: all male
Inclusion criteria: IC due to PAD (ABI < 0.95 at rest or < 0.85 after exercise)
Exclusion criteria: critical limb ischaemia; resting ankle blood pressure < 50 mmHg;
unable to walk on the treadmill at a speed of 2 mph or an exercise capacity limited
by angina, congestive heart failure, COPD, or arthritis; DM; vascular intervention in
previous year; treatment with beta-blockers or pentoxifylline
Interventions Treatment: programme of exercise 3 times each week (5 min warm up, 50 min intermit-
tent isotonic resistive exercise, 5 min cool down)
Control: maintain usual level of exercise
Duration: 12 weeks
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Outcomes Primary: treadmill test maximal walking time (2 mph at 0% slope, with a subsequent 3.
5% increase in slope every 3 min until forced to stop)
Secondary: calf blood flow venous occlusion plethysmography, concentration of plasma
carnitine at rest
Subjective indicators: perceived pain during exercise; walking-limited distance
Notes Hiatt 1990 included distance walked and claudication pain. Unfortunately these results
were not reported by treatment group but simply correlated with treadmill performance.
The correlation was good; therefore it may be assumed that significant improvement was
experienced by those receiving exercise therapy
Treadmill test: graded treadmill test (2 mph 0% grade, with a subsequent 3.5% increase
in grade every 3 minutes)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin toss
Allocation concealment (selection bias) High risk Coin toss
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Only for the carnitine analysis
Incomplete outcome data (attrition bias)
All outcomes
High risk All outcome data clearly reported. 25 en-
rolled, 6 discontinued (24% lost)
Selective reporting (reporting bias) High risk Maximum walking distance and claudica-
tion pain not reported for individual treat-
ment group but correlated with treadmill
performance
Other bias Unclear risk Small numbers (n = 19)
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Methods Study design: RCT
Method of randomisation: not stated
Exclusions post randomisation: 3 did not consent for muscle biopsy
Losses to follow-up: 2 in control group
Participants Country: USA
Setting: not stated
No. of participants: 29
Age: mean 67 years ± 6 years
Sex: male only
Inclusion criteria: 3-month h/o stable IC (Rose Questionnaire) limiting exercise suffi-
ciently to affect ability to perform routine activity; ABI < 0.94 at rest, < 0.73 after exercise
Exclusion criteria: rest pain, ulcer, gangrene; inability to walk on treadmill at > 2 mph;
exercise limited by angina, CHF, COAD, or arthritis; no DM, vascular surgery, or PTA
in previous year
Interventions Treatment: supervised treadmill walking exercise (n = 10) or strength training (n = 9) and
encouraged to walk alone for 2 days each week (treadmill 1 h 3 times a week, walking
until moderate pain, then rest)
Control: maintain usual level of activity (n = 10)
Duration: 12 weeks
Outcomes Primary: treadmill test pain-free and maximal walking distance (2 mph, 0% slope, with
a subsequent 3.5% increase in slope every 3 min until forced to stop)
ABI (resting and post exercise)
Notes Trial continued after 12weekswithout a control group; therefore later results not included
Strength training was less effective than treadmill exercise; only the latter was included
in the meta-analysis for statistical reasons
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data reported
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Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Small numbers
Hobbs 2005
Methods Study design: RCT
Method of randomisation: 2 × 2 factorial design, random number table
Exclusions post randomisation: not reported
Losses to follow-up: 4 of original 38 withdrew
Participants Country: UK
Setting: university department of vascular surgery, patients referred to IC clinic from
primary or secondary care
No. of participants: 34
Age: median 67 (63 to 72) years
Sex: 27 men, 7 women
Inclusion criteria: IC diagnosed by Edinburgh Claudication Questionnaire and reduced
ABI < 0.9, reviewed after 3 to 6 months; max walking distance 20 to 500 m
Exclusion criteria: significant aorto-iliac disease, inability to complete treadmill distance
to absolute claudication distance, MI, transient ischaemic attack, stroke or PTA in past
3 months, CHF, bleeding diathesis, glomerular filtration rate < 20 mL/min, CYP3A4 or
CYP2C19 inhibitor use
Interventions Treatment:
• Supervised exercise: 3-month, twice-weekly 1-hour physiotherapist-led exercise pro-
gramme. Given videotape of programme and encouraged to take log of exercise at home
• Cilostazol 100 mg twice daily, if side effects dosing halved for 1 week
• Exercise as above plus cilostazol
Control: best medical therapy
Duration: 6 months
Outcomes MWD
Pain-free MWD
ABI
Thrombin antithrombin complex
Prothrombin fragments 1 and 2
Plasminogen activator inhibitor
Tissue plasminogen activator
Notes Study authors contacted for means and SDs - received for BMT and supervised exercise
groups
Treadmill test: 3 km/h, 10% incline to MWD or 1000 m
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk 2 × 2 factorial design randomisation, ran-
dom number table
Allocation concealment (selection bias) Low risk Eligible participantswere randomised in a 2
× 2 factorial design to continue BMT only
or to receive BMT + supervised exercise,
BMT+ cilostazol, or BMT + supervised ex-
ercise + cilostazol. The 2 × 2 factorial de-
sign is well recognised as one of the most
robust study designs and allows for greater
interrogation of the data, as well as allow-
ing interaction of different treatments to be
assessed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Small numbers
Jansen 1991
Methods Study design: RCT
Method of randomisation: not described
Exclusions post randomisation: not described
Losses to follow-up: not described
Participants Country: Germany
Setting: community
No. of participants: 48
Age: not described
Sex: not described
Inclusion criteria: PAD stage II
Exclusion criteria: not stated
Interventions Treatment: training on treadmill 3.5 km/h 10% slope for 2 hours twice per week under
medical/physiotherapy supervision
Control: no training
Duration: 2 years
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Outcomes Primary: treadmill walking distance, pain-free and maximum
Secondary: ultrasound Doppler of arm and leg arteries
Notes Treadmill test: 3.5 km/h, 10% incline
Translated from German
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no further information avail-
able
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of whether all enrolled com-
pleted the study
Selective reporting (reporting bias) Low risk All prespecified outcomes stated
Other bias Low risk No evidence of other bias
Kakkos 2005
Methods Study design: RCT
Method of randomisation: “blind block telephone procedure” by means of computer
Exclusions post randomisation: 2 participants in the IPC group withdrew their consent
before their 6 weekly appointments
Losses to follow-up: 4 in supervised exercise group; 4 in IPC group
Participants Country: England
Setting: vascular out-patient clinic
No. of participants: 34
Age:median and IQR: 66 (10.5) unsupervised exercise (USE) group; 69 (11.8) supervised
exercise (SE) group; 66 (7) intermittent pneumatic compression (IPC) group
Sex: 27 M in total; 8 M USE group, 11 M SE group, 8 M IPC group
Inclusion criteria: stable IC for > 6 months due to superficial femoral artery occlusion
of ≥ 6 cm in length on ultrasound and/or angiogram
Exclusion criteria: duration of symptoms < 6 months, previous angioplasty or arterial
surgery to symptomatic leg, MI within previous 6 months, inability to manage treadmill
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or training, any psychiatric illness or other reason making follow-up difficult, ischaemic
rest pain, gangrene, ischaemic ulceration, inability to attend supervised programme,
severe peripheral neuropathy, ABI > 0.9 at enrolment, non-compressible calf arteries,
iliac occlusions or stenoses amenable to surgery or angioplasty, femoral artery occlusion
< 6 cm; exercise capacity limited by angina, congestive heart failure, COPD, disease of
spinal column, venous disease, neurological disease, mental illness, or arthritis
Interventions Treatment:
• Supervised (n = 12): 5-minute warm-up, 50-minute intermittent exercise, 5-minute
cool-down. Attendance was 3 times a week for 6 months
• Unsupervised exercise (n = 9); advised to walk for approximately 45 minutes each day
• Pneumatic foot compression (n = 13); to be used daily for 3-hour periods
Duration: 6-month treatment period plus further follow-up at 12months after treatment
began (exercise advice given for second 6-month period)
Outcomes Primary: ICD, ACD, ABI
Secondary: SF-36, WIQ, IC Questionnaire
Notes Study authors were successfully contacted for means and SDs.
Treadmill test: 3.5 km/h, 10% incline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised: blind, block telephone com-
puter generated randomisation, under-
taken by Clinical Trials and Evaluation
Unit
Allocation concealment (selection bias) Low risk Independent allocation
A blind, block ’telephone’ randomisation
procedure was performed by means of a
computer
Randomisationwas performedby theClin-
ical Trials and Evaluation Unit at the Royal
Brompton Hospital in London
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk 8 of 34 discontinued at 6 months (attrition
rate of 26%)
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Selective reporting (reporting bias) Low risk All data reported
Other bias High risk n = 8 per group. Power calculation required
15 participants per group
Larsen 1966
Methods Study design: RCT
Method of randomisation: randomised in pairs matched by age and disease, not blinded
Exclusions post randomisation: 0
Losses to follow-up: 0
Participants Country: Denmark
Setting: not stated
No. of participants: 14
Age: 44 to 65 years
Sex: male and female
Inclusion criteria: typical IC, stable for > 6 months
Exclusion criteria: none stated
Interventions Treatment: instructed to walk daily, in addition to normal activities
Control: 1 placebo (lactose) tablet bd
Duration: 6 months
Outcomes Primary: treadmill test MWD (4.6 km/h, elevation of 0, 8, or 16 cm/m)
Secondary: calf blood flow xenon clearance method
Notes Treadmill test differed for each participant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised in pairs matched by age and
disease. Not blinded
Allocation concealment (selection bias) High risk Not blinded
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants to exercise
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes stated
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Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Treadmill test different for each partici-
pant, small numbers (n = 14)
Leicht 2011
Methods Study design: RCT
Method of randomisation: (info from study author) Consecutive IC patients were ran-
domly allocated to each group via sealed envelopes that were developed by a researcher
not associated with the study
Exclusions post randomisation: nil stated
Losses to follow-up: described in detail in CONSORT chart (Leicht 2011)
Participants Country: Australia
Setting: local hospital and university centre
No. of participants: 25 PAD, 24 healthy age-matched controls
Age: 66.9 years (± 8 years)
Sex: 14 male (56%)
Inclusion criteria: PAD was confirmed based on absence of lower limb peripheral pulses,
lower limb artery stenosis, or occlusion on duplex or computed tomographic angiogra-
phy, and ankle brachial index (ABI) < 0.94
Exclusion criteria: inability to attend potential regular supervised exercise (n = 48),
selected for surgical or endovascular intervention (n = 30), declined (n = 20), other
medical condition influencing gait (n = 20), exhibited significant ectopy at rest (n = 3)
Interventions • Conservative medical treatment (n = 13)
• Supervised exercise (n = 12) consisted of treadmill walking 3 days per week for 25 to
40 minutes per day at a workload that induced intense to maximal claudication pain
Control: healthy age-matched controls (n = 24)
Duration: 12 months
Outcomes Primary: to compare heart rate variability (HRV) in patients with IC and in age-matched
healthy adults
Secondary: to examine the influence of an intense long-term (12-month) exercise pro-
gramme on HRV in patients with IC
PFWD, MWD, ABI
Notes Treadmill test: 3.2 km/h and incline of 0%. The incline increased by 2% every 2 minutes
until voluntary exhaustion or a maximum time of 25 minutes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, consecutive IC patients were
randomly allocated to each group via sealed
envelopes that were developed by a re-
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searcher not associated with the study
Allocation concealment (selection bias) Low risk Consecutive IC patients were randomly al-
located to each group via sealed envelopes
that were developed by a researcher not as-
sociated with the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data reported
Selective reporting (reporting bias) Low risk All outcome data reported
Other bias Unclear risk Small numbers
Mannarino 1991
Methods Study design: RCT
Method of randomisation: states random. Not blinded
Exclusions post randomisation: not stated
Losses to follow-up: none
Participants Country: Italy
Setting: not stated
No. of participants: 20
Age: 48 to 75 years
Sex: male and female
Inclusion criteria: IC for > 2 years, stable for past 3 months, pain-free walking distance
< 300 m
Exclusion criteria: h/o angina, recent MI, or stroke; vascular surgery or PTA in previous
6 months; impaired cardiac or lung function; major liver, kidney, or metabolic disorders;
infection; cancer; peptic ulcer
Interventions Treatment: 1 h home exercises daily supervised via out-patients. Week 1: 500 m in 20
min; week 2: 1000 m in 40 min; week 3: 2000 m in 60 min
Control: dipyridamole 75 mg tds plus aspirin 330 mg od
Duration: 6 months
Outcomes Primary: treadmill test pain-free and maximal walking time (2 km/h on 12° slope), ABI
Secondary: calf blood flow strain-gauge plethysmography
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Notes A third group of 10 participants received antiplatelet treatment and exercise. These results
are discussed but are not formally included in a meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no further information avail-
able
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of whether all enrolled com-
pleted the study
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Small numbers
McDermott 2008
Methods Study design: RCT
Method of randomisation: parallel assignment by computer via a randomly permuted
block method; outcome assessor blinded
Exclusions post randomisation: not described
Losses to follow-up: described in flow chart (McDermott 2008)
Participants Country: Chicago
Setting: urban academic medical centre
No. of participants: 156
Age: 70.6 ± 10.3 years
Sex: male and female
Inclusion criteria: 150 peripheral arterial disease patients with and without IC
Exclusion criteria: above or below knee amputation, wheelchair confinement, inability
to walk on a treadmill or perform progressive resistance training, inability to attend 3
times a week for 6 months, Class II NYHA heart failure or angina at rest or on minimal
exertion, silent coronary ischaemia (ST depression of 1 mm) during baseline exercise
test, ST-T wave changes or LBBB on baseline ECG, walking impairment not attributed
to PAD, planned lower extremity revascularisation or major surgery within 12 months,
MI or CABG during previous 3 months, current foot ulcer, ABI > 0.95, life expectancy
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< 12 months, does not speak English, dementia, poorly controlled BP, treated for cancer
in the past 12 months, current significant exercise
Interventions Treatment group 1: supervised treadmill exercise (6 months, 3 times a week; followed
by a 6-month home-based programme). Initially 15 minutes of exercise, increased to 40
minutes by week 8. Initial treadmill walking speed 2.0 mph. Between weeks 8 and 24,
intensity was increased weekly; either by grade or by speed, n = 51
Treatment group 2: lower extremity resistance training (6 months, 3 times a week;
followed by a 6-month home-based programme). Participants performed 3 sets of 8
repetitions of knee extensions, leg press, leg curl exercises. Weights adjusted monthly
until lifting 80% of 1 maximum repetition. 3 sets of 8 repetitions of squat and toe rises
were also performed, n = 52 (1 dropped out)
Control: usual care with diet and nutrition advice (11 sessions lasting 1 hour each over
6 months), n = 53 (1 dropped out)
Duration: 6 months
Outcomes 6-Minute walking test distance
Short physical performance battery
Brachial artery flow-mediated dilatation
Treadmill walking performance distance
WIQ
SF-36 physical functioning score
Notes Treadmill test: Gardner Skinner Protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised parallel assignment by com-
puter via a randomly permuted block
method
Allocation concealment (selection bias) Low risk Parallel assignment by computer via a ran-
domly permuted block method
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examiners were blinded to participant
group assignment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
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Other bias Unclear risk Underpowered. Power calculations as-
sumed that 50 people in each group would
complete 6-month follow-up, and that 2
separate 2-sample t-tests using a 2-sided al-
pha of 0.05would be conducted. The study
was designed to have 80% power to de-
tect a difference of 30 meters change in 6-
minute walk distance and a difference of
0.97 change in the SPPB between baseline
and 6-month follow-up between each ex-
ercise and control group
Only 50 completed the SET; 48 were in
the control group, and 46 were in the lower
extremity resistance group
McGuigan 2001
Methods Study design: RCT
Method of randomisation: randomly assigned to either of the 2 experimental groups
Exclusions post randomisation: 2 participants from the training group and 2 from the
control group withdrew from the study because of circumstances unrelated to the inves-
tigation
Losses to follow-up: not stated
Participants Country: Australia
Setting: not stated
No. of participants: 20 (sample size of 18 needed)
Age: not stated
Sex: male and female
Inclusion criteria: ABI < 0.94 at rest that decreased to < 0.73 after exercise
Exclusion criteria:
• Leg pain at rest
• Ischaemic ulceration or gangrene
• Inability to walk at least 2 km/h on a treadmill
• Limited exercise capacity by factors other than IC (e.g. symptoms of angina, CCF,
COPD, arthritis)
• Vascular surgery or angioplasty undergone within the previous year
• Smoking
Interventions Treatment: n = 11. Resistance training program 3 days per week throughout the 24-week
period. Minimum of 48 hours between sessions
Control: n = 9
Duration: 24 weeks
Outcomes Aims: to investigate effects of resistance training on walking performance, strength, and
skeletal muscle adaptation
Primary: fibre area and shifts in MHC isoforms
Secondary:
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• Graded treadmill protocol - initially 3 km/h at 0% for 2 min, then increased 2% every
2 min with speed constant
• Rate of perceived pain (scale 0 to 10)
• Time in seconds to onset of claudication pain or maximal claudication pain
• 6-minute walk
• ABI
• Fibre type and distribution
• Muscle capillarisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated. Randomly assigned to either of
the 2 experimental groups
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Two participants from the training group
and 2 from the control group withdrew
from the study because of circumstances
unrelated to the investigation
Unclear what total numbers were
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Sample size was 18, which was not met, as
4 withdrew.
Mika 2005
Methods Study design: RCT
Method of randomisation: not described
Exclusions post randomisation: not described
Losses to follow-up: 18 withdrew (10 control, 8 exercise)
Participants Country: Poland
Setting: university department out-patient clinics
No. of participants: 98
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Age: 50 to 70 years
Sex: male and female
Inclusion criteria: PAD and IC (Fontaine stage II) stable for 3 months, PFWD 50 to
200 m at 3.2 km/h
Exclusion criteria: angina, recent MI, vascular surgery in past 3 months, impaired car-
diac or lung function, DM, cancer, kidney and liver disease, arthritis limiting walking,
other contraindication to walking, those taking beta-blockers, pentoxifylline or other
haemorheologically active drugs
Interventions Treatment: 12-week programme of supervised pain-free treadmill exercise, 1 hour per
day 3 times a week of repetitive walking exercise
Control: usual care
Duration: 3 months
Outcomes PFWD
Total leukocyte count
Neutrophil count
Microalbuminuria
Notes Treadmill test: 3.2 km/h, 12% incline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no further details available
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessor. Testing and analyses
were conducted by qualified medical staff
blinded to participants’ group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No evidence of other bias
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Mika 2006
Methods Study design: RCT
Method of randomisation: not described
Exclusions post randomisation: not described
Losses to follow-up: 5
Participants Country: Poland
Setting: university department clinics
No. of participants: 60
Age: 50 to 70 years
Sex: male and female
Inclusion criteria: Fontaine stage II PAD, IC limiting walking and stable for 3 months,
ABI < 0.9
Exclusion criteria: angina; recent MI; vascular surgery in past 3 months; impaired car-
diac or lung function; DM; cancer, kidney, and liver disease; arthritis limiting walking;
inability to walk at 3.2 km/h; taking beta-blockers, pentoxifylline, or other haemorheo-
logically active drugs
Interventions Treatment: 12-week programme of supervised pain-free MD treadmill exercise, 1 hour
per day 3 times a week of repetitive walking exercise
Control: usual care, to maintain normal activity level
Duration: 3 months
Outcomes Pain-free walking time
Maximum walking time
Red cell deformability - erythrocyte elongation index
Notes Treadmill test: 3.2 km/h 0% for 3 minutes followed by an increase in grade of 3.5%
every 3 minutes (speed remained constant)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no further details available
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 lost to follow-up (3 in exercise group, 2
in control group). All data on remaining 55
reported
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Selective reporting (reporting bias) Low risk All data on remaining 55 reported
Other bias Unclear risk Patients who were unable to walk on the
treadmill at a speed of at least 3.2 km/h
were also excluded
Mika 2011
Methods Study design: RCT
Method of randomisation: not stated
Exclusions post randomisation: not stated
Losses to follow-up: 7 dropped out
Participants Country: Poland
Setting: hospital; vascular out-patient clinic
No. of participants: 68
Age: 63.5 years (training group), 62.1 years (control group)
60 male, 8 female
Inclusion criteria: PAD and IC - Fontaine stage II, aged 50 to 70 years, ABI < 0.9 at rest
and 0.75 after exercise. All included patients had stable claudication distance and were
able to walk no less than 150 m without pain
Exclusion criteria: rest pain, gangrene, ulceration, history of angina pectoris, recent MI
or vascular surgery within the previous year, impaired cardiac or lung function, DM,
cancer, or kidney and liver disease. Also, patients with arthritis who were unable to walk
on the treadmill at a speed of at least 3.2 km/h. Additionally, women in menopausal
status and those taking oestrogen were excluded because of the possible effects of these
factors on HDL cholesterol level. None of the participants in the study was taking beta-
blockers
Interventions Treatment: 12-week SEP, sessions conducted in the morning, 3 times per week
Repetitive walking exercise with 3-min resting intervals. During each session, after 5min
of warm-up activities (free cycling on a stationary cycle ergometer), participants walked
on the treadmill at a speed of 3.2 km/h at a grade that induced claudication pain within
approximately 3 to 5 min
Control: no change in physical activity
All study participants were encouraged to stop smoking. Their diet was neither controlled
nor modified throughout the study period
Duration: 3 months
Outcomes Pain-free walking time (PFWT)
Maximal walking time
Haematocrit
Plasma lipoproteins
Notes Graded treadmill protocol (Gardner protocol): 3.2 km/h throughout the test, but the
inclination from 0% (during initial stage) was raised by 2% every 2 min until maximal
claudication pain occurred; without handrail
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Mika 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned to either an interven-
tion group (n = 34) or a control group (n
= 34)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treadmill testing and biochemical analyses
were conducted by medical staff blinded to
participants’ group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 dropouts discussed; rest of data complete
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk During an initial visit, participants were
familiarised with treadmill walking (speed
3.2 km/h, 0% inclination) for 10 min.
The treadmill test was repeated on the next
day, and the mean of 2 measurements was
used in data analysis. The treadmill was
calibrated before each testing. Participants
were instructed not to use handrail support
during the test
Sanderson 2006
Methods Study design: RCT
Method of randomisation: closed envelope system
Exclusions post randomisation: nil
Losses to follow-up: 1 in treadmill group
Participants Country: Australia
Setting: not stated
No. of participants: 42
Age: mean 63 years
Inclusion criteria: claudication lasting > 1 year, ABI < 0.9
Exclusion criteria: reduced cardiac function, rest pain, recent surgery or cardiac event,
other medical conditions rendering exercise unsuitable
72Exercise for intermittent claudication (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sanderson 2006 (Continued)
Interventions Treatment:
• Treadmill exercise
• Cycling
Both groups exercised 3 times a week for 6 weeks
Control: no exercise
Duration: 6 weeks
Outcomes MWD and PFWD and cycling tests
Submaximal and peak physiological response
ABI
Notes Stratified by gender, presence of diabetes, then randomised
Results given as mean differences
The maximal graded walking test was performed on a motorised treadmill (TrackMaster
TMX425CP, Newton, Kan) at a constant speed of 2.7 km/h. The treadmill gradient was
set at 0% for the first 5 minutes of the test, then it was increased by 2% every 3 min
until the participant failed to sustain the task
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Closed envelope system
Allocation concealment (selection bias) Low risk Closed envelope system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No evidence of other bias
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Schlager 2011
Methods Study design: RCT single centre
Methodof randomisation: computer-generated randomdigits in sealed envelopes (block-
wise randomisation by 2)
Exclusions post randomisation: nil
Losses to follow-up: 1 (MI 3 months after study inclusion)
Participants Country: Austria
Setting: single-centre hospital
No. of participants: 40
Age: mean age of 69.1 years (standard deviation of ± 9.5 years)
Inclusion criteria: symptomatic PAD (Rutherford category I to III), diagnosed by clinical
evaluation, oscillometric pulse wave measurements, ABI, duplex sonography, and or CT
or MR angiography
Exclusion criteria: asymptomatic PAD, critical limb ischaemia and reduced exercise tol-
erance caused by other limitations than claudication (coronary artery disease, congestive
heart failure, dyspnoea, uncontrolled blood pressure, any kind of restriction of the mus-
culoskeletal system, which might have an influence on the efficiency of exercise training)
Interventions Treatment: SEP with BMT (twice-weekly programme for 6 months). Warm-up period
of 5 to 10 min; initial duration included 35 min of intermittent walking, which was
increased by 5 min each session until 50 min of intermittent walking was accomplished.
The workload of exercise training was set to a walking speed that elicited claudication
symptoms within 3 to 5 min
Control: BMT
Duration: 12 months
Outcomes Endothelial progenitor cells (CD34+, CD133+, KDR+)
Plasma levels of vascular endothelial growth factor (VEGF), asymmetrical dimethylargi-
nine (ADMA), stromal cell derived factor-1 (SDF-1)
Maximum walking distance
Notes Treadmill test: 3.2 km/h, 12% incline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random digits in
sealed envelopes (block-wise randomisa-
tion by 2)
Allocation concealment (selection bias) Low risk Computer-generated random digits in
sealed envelopes (block-wise randomisa-
tion by 2)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treadmill exercise tests were routinely per-
formed by 2 experienced medical techni-
cal assistants, who were blinded to the as-
signed treatment arm and otherwise were
not involved in the study. Participants were
instructed to report all symptoms and dis-
comforts (claudication andother than clau-
dication) occurring during the test, but as-
sistants refrained from encouraging partic-
ipants during treadmill exercise tests
Incomplete outcome data (attrition bias)
All outcomes
Low risk One out of 40 participants did not com-
plete the study.
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No evidence of other bias
Tew 2009
Methods Study design: RCT
Method of randomisation: computer programme (nQuery Advisor 6.0 Statistical solu-
tions)
Not blinded
Exclusions post randomisation: none
Losses to follow-up: 2 withdrew from the exercise group, and 4 withdrew from the
control group; 1 participant died of a heart attack, 1 developed a lower limb ulcer that
required revascularisation surgery, 1 was identified as having a popliteal artery aneurysm,
and 1 returned to full-time employment. The remaining 2 participants cited lack of time
as their reason for withdrawal
Participants Country: England
Setting: single-centre hospital
No. of participants: 57
Age: 69 ± 9 years
Sex: male and female
Inclusion criteria: Fontaine stage II PAD, 12-month history of stable IC, ambulation
limited by IC, resting ABI < 0.90 or ABPI drop > 15 mmHg post maximal walking
exercise
Exclusion criteria: absence of PAD, ABI unobtainable owing to incompressible vessels,
Fontaine I or III, exercise limited by cause other than IC, history of IC < 12 months,
revascularisation/other major surgery within past 12 months, pharmacological therapy
specifically for IC (e.g. cilostazol)
Interventions Treatment:
• Arm crank exercise (twice-weekly exercise programme for 12 weeks at an intensity of
60% to 70% of the peak work rate achieved of the initial arm crank assessment. Patients
trained in cycles of 2-minute exercise at 50 rev/min followed by 2 min of rest for a total
75Exercise for intermittent claudication (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tew 2009 (Continued)
of 40 min/session)
Control:
• Non-exercise group
Duration: 3 months
Outcomes Primary: lower limb oxygen delivery
Secondary: NIRS, peak VO2 kinetics
Notes Treadmill test: 3.2 km/h, 0% grade with 1% increase every 1 min
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised via a computer programme
(nQuery Advisor 6.0; Statistical Solutions)
Allocation concealment (selection bias) Low risk Computer programme (nQuery Advisor 6.
0; Statistical Solutions)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 from the exercise group and 4 from the
control group
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Methodological limitations need to be con-
sidered: NIRS data;exact contribution of
intracellular myoglobin to the StO2 signal
is unclear, and subcutaneous fat thickness
changes might have influenced findings
No relationship exists between calf skinfold
and calf muscle StO2 during walking in
patients with IC
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Tew 2015
Methods Study design: RCT
Method of randomisation: randomised ratio 2:3. Achieved via a block randomisation
sequence (block size 10) generated before recruitment
Exclusions post randomisation: none
Losses to follow-up: 1 lost to follow-up, all accounted for within CONSORT diagram
Participants Country: UK
Setting: not stated
No. of participants: 23
Age: > 18
Sex: men and women
Inclusion criteria: age > 18 years and stable IC for > 3 months
Exclusion criteria: CLI, planned or previous lower-limb revascularisation, presence of
contraindications to exercise (e.g. unstable angina) or co-morbidities that limitedwalking
to a greater extent than the IC (e.g. severe arthritis); major surgery, MI, or CVA in the
previous 6 months
Interventions Treatment: usual care + SEDRIC (structured education for rehabilitation in intermittent
claudication programme that promotes self-managed walking in people with IC)
Control: usual care (included a brief info leaflet on PAD)
Duration: 6 weeks
Outcomes Mean daily step count
Pain-free and maximum walking distances
6-min walking distance
WELCH questionnaire, WIQ, EQ-5D, Intermittent Claudication Questionnaire
Notes Gardner incremental treadmill test: 3.2 km/h, 0% grade, with 2% increase every 2 min
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised ratio 2:3. Achieved via a block
randomisation sequence (block size 10)
generated before recruitment
Allocation concealment (selection bias) Low risk Implemented by an individual whowas not
involved in recruitment or data gathering
processes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Group allocation was concealed from par-
ticipants while baseline information was
gathered
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All stated
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Baseline data showed that the intervention
group had slightly higher levels of physical
activity, walking capacity, and quality of life
than the control group
Tisi 1997
Methods Study design: RCT
Method of randomisation: randomised by sealed envelope, weighted 70:40:40 (angio-
plasty:exercise:observation)
19/25 randomised to PTA had unsuitable lesions, and the technique failed in one other.
Not blinded
Intention-to-treat analysis
Exclusions post randomisation: none stated
Losses to follow-up: none stated
Participants Country: England
Setting: general hospital
No. of participants: 67
Age: mean 69.3 years
Sex: male and female
Inclusion criteria: stable IC > 6months, positive EdinburghClaudicationQuestionnaire,
ABI < 0.8 and > 3 0 mmHg drop in ankle systolic pressure on exercise, walking distance
50 to 250 m on treadmill (3 km/h, 10% gradient)
Exclusion criteria: intervention for IC in past 6months, exercise limited by other factors,
concurrent medical disease, treatment with steroids, inability to complete assessment
visits
Interventions Treatment:
• Exercise - series of active and passive leg exercises performed to the limit of exercise pain,
supervised by a physiotherapist once weekly for 4 weeks. Also encouraged to exercise for
45 min daily at home, plus to walk 1 mile a day; n = 22
• PTA, n = 28
• Control: observation, plus advice given to all 3 groups (leaflet advising on weight loss,
smoking, and exercise, plus 75 mg aspirin daily), n = 17
• Healthy controls, n = 15
Duration: 12 months
Outcomes Primary: treadmill test - PFWD and MWD (3 km/h on 10% slope); ABI
Secondary: Nottingham Health Profile
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Notes Results for the exercise versus angioplasty comparison have not been included in this
review.
Claudication and walking distance results not in usable format
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by sealed
envelope, weighted 70:40:40 (angioplasty:
exercise:observation)
Allocation concealment (selection bias) Unclear risk Randomised by sealed
envelope, weighted 70:40:40 (angioplasty:
exercise:observation); opacity of envelopes
not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in paper
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 22 enrolled at baseline, 10 were
present at 12 months in the exercise group.
In the observation group, n = 17 at base-
line, and n = 9 at 12 months. No reasons
given for loss to F/U
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No evidence of other bias
Tsai 2002
Methods Study design: RCT
Method of randomisation: not described
Exclusions post randomisation: not described
Losses to follow-up: 11 - 5 in treatment group, 6 in control group
Participants Country: Taiwan
Setting: community
No. of participants: 64
Age: 76 years ± 4
Sex: 81% male
Inclusion criteria: Fontaine II PAD on Rose Questionnaire. ABI < 0.95
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Exclusion criteria: intervention for IC in past 3months, exercise limited by other factors,
rest pain, MI or unstable claudication in the past 3 months, history of angina on exertion
Interventions Treatment: 12-week progressive rehabilitation programme, 3 times a week. Up to 30
minutes on the treadmill
Control: usual care
Duration: 12 weeks
Outcomes Time to onset of pain
Time to maximum pain
6-Minute walking test distance
WIQ
Physical function
Bodily pain
Role limitation physical and emotional
General health
Mental health
Social function
Vitality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no further details available
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No evidence of other bias
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Methods Study design: RCT
Method of randomisation: not stated by paper
Not blinded
Exclusions post randomisation: none stated
Losses to follow-up: nil stated
Participants Country: Australia
Setting: vascular out-patient clinic at the Royal Brisbane and Women’s Hospital
No. of participants: 18
Age: 56 ± 9 control, 64 ± 6 treatment
Sex: male and female
Inclusion criteria: history (> 6 months) of stable PAD and IC
Exclusion criteria: rest pain, unstable angina and/or uncontrolled hypertension, experi-
enced loss of consciousness as a result of dizziness, had a bone or joint problem that could
be exacerbated by exercise, had undergone vascular surgery within the past 6 months,
had suffered a cerebrovascular or coronary event in the past 12 months, or resided more
than 1 h by car from the laboratory. Patients not limited by claudication and those who
experienced angina or demonstrated ischaemic ECG abnormalities during exercise were
excluded from the study
Interventions Treatment:
• 6 weeks of treadmill walking training, three 40-min supervised walking training ses-
sions/week (n = 7)
Control: sedentary control (n = 6)
Participants in both groups were asked to continue their normal daily activities
Duration: 6 weeks
Outcomes • To determine whether plasma vascular endothelial growth factor (VEGF) increases
in response to acute exercise in patients with IC, given the potentially large hypoxic
stimulus for VEGF release during exercise in this population
• To determine whether this response is attenuated following 6 weeks of high-intensity
exercise training
Notes Treadmill test: 2.7 km/h, 0%, with grade increased 2% every 3 min
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “In part B participants were randomised to
one of two study arms”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to bind participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk n = 6 for control and n = 7 for training. Nil
lost to follow-up
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk Small numbers in each arm
Zwierska 2005
Methods Study design: RCT
Method of randomisation: Randomisation was undertaken via the fishbowl technique
(Baumgartner 1998). This involved drawing patient names out of a ’hat’ and allocating
them to respective groups at random. Randomisation was undertaken by an independent
academic based at another site in Sheffield
Intention-to-treat analysis: yes
Exclusions post randomisation: nil
Losses to follow-up: 10
Participants Country: UK
Setting: not stated
No. of participants: 104
Age: median 69 (50 to 89)
Sex: 81% male in leg group, 78% in arm group, 73% in control group
Inclusion criteria: stable symptomatic peripheral arterial disease
Exclusion criteria: not stated
Interventions Treatment:
• Supervised upper limb aerobic exercise
• Supervised lower limb aerobic exercise
Control: no exercise
Duration: 24 weeks
Outcomes ICD
MWD
Peak heart rate
Peak oxygen consumption
Perceived exertion and pain
Physical activity status
Notes Results given as medians - study authors contacted successfully for more information
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomised
Randomisation was undertaken via the
fishbowl technique (Baumgartner and
Strong 1998). This involved drawing pa-
tient names out of a ’hat’ and allocating
them to respective groups at random
Allocation concealment (selection bias) Low risk Randomisation was undertaken by an in-
dependent academic based at another site
in Sheffield
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessment of outcome measures was con-
ducted by the same 2 staff members. Proce-
dures were checked for consistency at ran-
dom by the lead investigator at Sheffield
Hallam University (J.S.), who was blinded
to group assignment
Blinding of the 2 staff members who as-
sessed outcome measures was not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data clearly reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No evidence of other bias
ABI: ankle brachial index.
ABPI: ankle brachial pressure index.
ACD: absolute claudication distance (or maximum walking distance).
bd: twice a day.
BMI: body mass index.
BMT: best medical therapy.
bpm: beats per minute.
CABG: coronary artery bypass graft.
CCF: congestive cardiac failure.
CHF: congestive heart failure.
CLI: critical limb ischaemia.
COAD: chronic obstructive airways disease.
COPD: chronic obstructive pulmonary disease.
CPAD-IC: peripheral arterial disease with intermittent claudication control group.
CPS: composite pain scale.
CT: computed tomography.
CTA: computed tomographic angiography.
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CVA: cerebrovascular accident.
DM: diabetes mellitus.
ECG: electrocardiography.
EQ-5D: EurQoL Group Quality of Life Questionnaire based on 5 dimensions.
HbA1c: glycated haemoglobin.
HDL: high-density lipoprotein.
h/o: history of.
HRQoL: health-related quality of life.
HRV: heart rate variability.
ICQ: Intermittent Claudication Questionnaire.
IQR: interquartile ratio.
LBBB: left bundle branch block.
LDL: low-density lipoprotein.
IC: intermittent claudication.
ICD: intermittent claudication distance.
IHD: ischaemic heart disease.
IPC: intermittent pneumatic compression.
MI: myocardial infarction.
min: minutes.
MR: magnetic resonance.
MWD: maximum or maximal walking distance.
NIRS: near-infrared spectroscopy.
NO: nitric oxide.
NYHA: New York Heart Association.
od: once a day.
PAD: peripheral arterial disease.
PFWD; pain-free walking distance.
PTA: percutaneous transluminal angioplasty.
RCT: randomised controlled trial.
SD: standard deviation.
SDF-1: stromal cell derived factor-1.
SE: supervised exercise.
SEP: supervised exercise programme.
SET: supervised exercise therapy.
SF-36: Short Form-36.
SPPB: Short Physical Performance Battery.
TASC: Trans-Atlantic Inter-Society Consensus.
tds: three times a day
TPAD-IC: peripheral arterial disease with intermittent claudication treatment group.
USE: unsupervised exercise.
VEGF: vascular endothelial growth factor.
vit E: vitamin E.
VO2: maximum volume of oxygen.
WELCH: Walking Estimated-Limitation Calculated by History.
WIQ: Walking Impairment Questionnaire.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allen 2010 Compares home and supervised based programmes with a focus on nitrite flux
Andreozzi 2008 All 4 study arms utilised exercise.
Aruna 2015 Unclear whether symptomatic PAD. Methods state only that patients had type 2 diabetes mellitus for > 4
years and ABI between 0.90 and 0.40
Beutel 1985 Both groups included exercise; the RCT compared CO2 mineral baths vs CO2 gas baths.
Bronas 2011 The usual care group was provided with an exercise regimen that participants could decide whether to follow or
not. Therefore, the study compares supervised vs non-supervised exercise. “Control participants also received
written instructions on how to exercise independently if they so chose to do”
Brotons 2011 This RCT focussed on all patients with “a diagnosis of ischaemic heart disease, stroke or peripheral arterial
disease”, and the “primary endpoint was the combination of all-cause mortality and hospital cardiovascular
readmission”
Separate outcomes for each group were not provided.
Buchwalsky 1974 2 training groups
Bulling 1991 Comparison of exercise plus gingko biloba and exercise vs placebo. No non-exercise control group
Cachovan 1999 Comparison of 2 different sequences of exercise. No non-exercise control group
Carmeli 2004 Not randomised
Cheetham 2004 2 exercise groups and no non-exercise control group
Choi 2012 2 exercise groups and no non-exercise control group. “Controlled clinical trial with two intervention arms:
calf ergometry and treadmill training”
Cina 1996 Comparison of physical training vs low-dose heparin and physical training and placebo. No non-exercise
control group
CLEVER 2009 This study compares relative clinical and cost-effectiveness of invasive revascularisation with stents vs super-
vised exercise rehabilitation
Collins 2010 Satisfied inclusion criteria, but data not available in usable format despite attempt to contact trial author
Collins 2012 Comparison of 2 different sequences of exercise. No non-exercise control group. “Patients were randomized
to a traditional walking program or walking with poles program of exercise training”
Creasy 1990 This study compared PTA vs supervised exercise therapy.
Crowther 2008 Supervised exercise vs usual care, which included exercise advice for both groups
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Cucato 2011 Methodology not of anRCT: 8participants randomly underwent 2 experimental sessions: a session of resistance
exercise (6 exercises, 3 sets of 12, 10 and 8 repetitions with perceived exertion of 11 to 13 on the 15-grade
Borg scale) and a control session (resting on exercise machines)
Cucato 2011a The aim of this study was to compare effects of walking and strength training on cardiovascular responses
assessed at rest and during exercise in patients with intermittent claudication
Cucato 2015 Participants with IC participated in 2 experimental sessions in a random order. Walking exercise (WE) (15
× 2-min bouts of WE interpolated with 2-min rest intervals) and control (standing rest on a treadmill for
60 min). BP, cardiac output (CO: CO2 rebreathing), and cardiovascular autonomic modulation (spectral
analysis of heart ratevariability) were assessed before and after both experimental sessions during supine rest,
and stroke volume and systemic vascular resistance were calculated
Cunningham 2012 This trial assessed whether a brief psychological intervention could increase daily walking at 4 months. The
control group received usual care plus researcher contact, and the treatment group received usual care and a
brief psychological intervention to modify illness and walking beliefs and to develop a personalised walking
action plan
Dahllof 1976 This trial was not fully randomised, as the first 10 of the 34 participants were allocated to exercise before
randomisationwas introduced.Therewere several differences between treatment and control groups, including
significantly higher cholesterol levels and maximal calf blood flow in the control group. Treatment effects may
also have been masked because many control participants spontaneously undertook increased exercise during
the trial period
Dantas 2016 Randomised cross-over intervention study with outcome measures of systolic BP, diastolic BP, and heart rate
Dedes 2010 Compares calf ergometry vs standard treadmill training (both groups involve exercise)
Degischer 2002 Not a randomised trial, and both groups had exercise
Dittmar 1977 Exercise in addition to drug treatment
Ericsson 1970 This trial compared exercise with no treatment but was excluded from the review because of insufficient
evidence that participants were randomised. The paper stated that participants were “divided into two groups”,
and trialists were approached to confirm the method of allocation. No reply was received; therefore it was
decided to exclude results from the review, unless evidence to the contrary becomes available
Ernst 1987 This trial compared participants on an exercise programme with those not exercised, but allocation was not
strictly randomised, as participants were “assigned according to space on the exercise programme”
Ernst 1990 Comparison of treadmill exercise plus pentoxifylline and treadmill exercise plus placebo. No non-exercise
control group
EXERT 2009 Participants in the control group will continue to receive usual care from their regular doctor for treatment
of PAD and will be provided with written exercise instructions
EXITPAD 2010 Both groups have compare supervised exercise vs walking advice
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Fakhry 2011 Home-based exercise compared to supervised exercise
Fitzgerald 1971 This trial compared an exercise regimen with no treatment, but no evidence in the report indicates that the
groups were randomly allocated. The quality of the trial appears generally poor, with variable periods of
follow-up and inclusion of some patients who did not have intermittent claudication
Fowler 2002 Some patients were asymptomatic, and it was not possible to exclude them for data extraction purposes
Gardner 2005 2 exercise groups compared
Gardner 2011 Home-based exercise compared to supervised exercise, and third control group given walking advice
Gardner 2012 No exercise, usual care control group encouraged to walk more on their own but did not receive specific
recommendations regarding an exercise programme during the study
Gardner 2014 80 participants were randomised to home-based and supervised exercise programmes. Both groups received
training
Gardner 2014a 180 participants were randomised. The NEXT Step programme and the supervised exercise programme
consisted of intermittent walking to mild to moderate claudication pain for 12 weeks, whereas controls
performed light resistance training
Gibbellini 2000 Satisfied inclusion criteria but no usable data, despite attempts to contact trial authors. Results divided into
asymptomatic and symptomatic groups, not aggregated
Gibbs 2013 This study is not focussed on patients with PAD. Participants (n = 140) with uncomplicated Type 2 Diabetes
Mellitus, and without known cardiovascular disease or PAD, aged 40 to 65 years, were randomised to super-
vised aerobic and resistance training 3 times per week for 6 months, or to a usual care control group. ABI was
measured before and after the intervention
Gottstein 1987 Both groups received training.
Greenhalgh 2008 Both groups included exercise with the addition of PTA as the modality being investigated
Guidon 2013 Focused on dropout rate of trials. Recruitment to clinical trials of exercise presents significant challenges in the
PAD population owing to the presence of coexisting cardiovascular and cerebrovascular disease, reluctance to
exercise due to leg pain, and acceptance of reduced mobility as part of ageing. Early identification in primary
care before the onset of significant comorbidity may ameliorate some of these issues
Guirro 2015 A cross-over study was carried out with 1 session of each therapeutic resource (high-voltage electrical stimula-
tion (HVES), continuous short-wave diathermy, or physical exercise), with a 7-day washout period between
protocols
Hobbs 2006 This study compared exercise with angioplasty.
Hodges 2008 Groups were given supervised exercise or normal care, which included walking advice
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Holm 1973 Suitable for review but no usable numerical data, despite attempt to contact trial author. Stated significant
improvement in walking time in exercise group compared to placebo group
Jones 1996 Comparison of treadmill vs StairMaster. No non-exercise control group
Kiesewetter 1987 Both groups received intensive physical therapy. No non-exercise control group
Kono 2013 This study is not focussed on patients with PAD. An observer-blind randomised controlled trial that enrolled
70 patients (48 men, mean age 63.5 years) with acute non-cardioembolic mild ischaemic stroke. Participants
were allocated in equal numbers to a lifestyle intervention group or a control group
Krause 1976 Combines exercise with drug
Kruidenier 2011 Treatment groups received angioplasty or exercise and angioplasty. A third group of exercise is required to
make the trial eligible for inclusion in the review
Labs 1999 Comparison of constant-load and graded-load treadmill testing with and without beraprost sodium. No non-
exercise control group
Lee 2007 Non-randomised (clinical and cost-effectiveness)
Leon 2005 Focussed on cardiovascular disease, not intermittent claudication
Lepantalo 1984 Comparison of exercise plus flunarizine and exercise plus placebo. No non-exercise control group
LIFE Study Original study is a multi-centred RCT that compared the ability of a structured physical activity intervention
vs a successful ageing intervention to prevent mobility disability in older sedentary people, not specifically
those with PAD
Lundgren 1989 This study compared exercise vs surgical reconstruction.
Maejima 2005 Satisfied inclusion criteria, but no data available after attempt to contact trial authors. Reported improvement
in walking time in exercise group at 12 weeks
Mannarino 1988 Controlled, not randomised
Mannarino 1989 This trial compared an exercise regimen with nothing (placebo tablets), but the report suggested that groups
were not allocated by an acceptable randomisation method. Trialists have been approached to confirm the
method of allocation; therefore it may become possible to include the trial at a later date
Martinez 2009 3 groups with different durations of a walking programme
Mays 2015 Participants with PAD randomised to a community-based walking exercise programme compared to usual
care advice. Control group received verbal advice to exercise but no formal training
Mazari 2010 This trial compares PTA, a supervised exercise programme (SEP), and combined treatment (PTA plus SEP)
for intermittent claudication
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McDermott 2004 Participants did not have intermittent claudication.
Nawaz 1999 Both groups received exercise advice. No non-exercise control group
Nawaz 2001 Comparison of upper limb and lower limb exercise. Separate non-randomised control group
NCT01065740 Outcome measure of 6-minute walking distance, not treadmill walking distance
NCT01241747 Treadmill training vs light resistance training without any walking
NCT02075502 Participants with PAD randomised to an exercise programme in the community setting incorporating training,
monitoring, and coaching compared with participants who received the standard of care (exercise advice)
NCT02879019 Both groups use exercise.
Necker 2003 Training after angioplasty
Nicolai 2010 This paper compared 4 different graded treadmill protocols in random order
Nielsen 1977 Both groups had exercise. No non-exercise control group
Nordanstig 2011 “All patients received verbal training advice and a written programme for IC. The patients were instructed to
walk 1/hr day and up to MWD as often as possible”
No arm received no exercise advice.
Parr 2009 All groups had exercise, no non-exercise control group. 3-armed trial of upper body strength training pro-
gramme, conventional exercise programme, and walking advice for the control group
Patterson 1997 Comparison of supervised exercise programme plus lectures and home-based exercise plus lectures. No non-
exercise control group
Pinto 1997 2 exercise regimens
Presern-Strukelj 200 Comparison of standard exercise alone and standard exercise plus electrostimulation in amputees with PAD
PROPEL study Comparison between those with and without PAD. Looks at baseline data without exercise
Riccioni 2010 No mention of randomisation in methods
Richardson 1991 This compared rocker-bottomed shoes vs normal shoes with respect to walking distances
Riebe 2001 Comparison of 2 progressive treadmill tests. No non-exercise control group
Ritti-Dias 2010 No control arm; strength training vs walking
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Rodrigues 2014 Randomised cross-over of participants with PAD who performed 2 experimental sessions: control (C) and
resistance exercise (R). Both sessions were identical (8 exercises, 3 × 10 reps), except that R session was
performedwith intensity between 5 and 7 on the OMNI-RES scale, and the C session was performed without
any load
Saleem 2011 Each group received exercise training. No non-exercise control group
Savage 2001 Compared supervised exercise vs home-based exercise. No non-exercise control group
Scheffler 1991 Each group received exercise training. No non-exercise control group
Schlager 2011a Satisfied inclusion criteria but data not available in usable format despite attempt to contact trial author
Schoneberger 1994 Controlled study, not randomised
Silvestro 2002 Age-matched control group
Slordahl 2005 2 exercise groups
Snabl 1958 Not a randomised controlled trial
Sonaglia 2013 2 exercise groups. Eligible PAD La Fontaine IIa-IIb participants were randomised into 2 groups. Group A
was treated with physical therapy plus oral pRLX, 20 ug b.i.d. for 12 weeks, and group B received physical
therapy alone
Spronk 2009 This study compared endovascular revascularisation vs supervised exercise
Stewart 2008 Supervised exercise vs exercise advice. No control group
Streminski 1992 Satisfied inclusion criteria but data not available in usable format despite attempt to contact trial author.
Actovegin vs exercise. Results given as mean change. Reported improvement in pain-free walking distance in
exercise group
SUPER study This study compared initial PTA vs initial supervised exercise therapy
Taft 2004 This study was not truly randomised and did not contain any outcomes of relevance to this review
Tebbutt 2011 Satisfied inclusion criteria but data not available in usable format despite attempt to contact trial author
Thomson 1999 2 exercise groups
Treat-Jacobson 2012 Participants with IC were assessed before and after a 12-week progressive, 3 times a week, supervised aerobic
arm exercise training programme. No control arm
Ventura 1984 Satisfied inclusion criteria but data not available in usable format despite attempt to contact trial author
Walker 2000 The non-exercise group was not randomised.
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Waller 1988 Comparison of exercise when participants had smoked immediately before treadmill test vs exercise when
participants had not smoked before treadmill test
Wang 2008 Treatment: Plantar Flexion Ergometer, this occurred 3 times a week for 8 weeks. Each session lasted 40minutes
with equal time on each leg
Control: received advice in accordance with existing exercise guidelines for PAD patients provided by the
AHA
Wang 2010 The study design was that of a cross-over from control to exercise, not a randomised controlled trial
Winterfeld 1983 Not a randomised controlled trial
Zwierska 2004 Both groups had exercise. No non-exercise control group
ABI: ankle brachial index.
AHA: American Heart Association.
BP: blood pressure.
b.i.d.: twice daily.
CO2: carbon dioxide.
IC: intermittent claudication.
MWD: maximum walking distance.
PAD: peripheral arterial disease.
PTA: percutaneous transluminal angioplasty.
RCT: randomised controlled trial.
SEP: supervised exercise programme.
WE: walking exercise.
Characteristics of ongoing studies [ordered by study ID]
NCT01231360
Trial name or title The Effect of Exercise Training on Skeletal Muscle Metabolism in PAD
Methods Allocation: randomised
Intervention model: parallel assignment
Participants Ages eligible for study: 40 years and older
Genders eligible for study: both
Accepts healthy volunteers: yes
Inclusion criteria:
• Claudication symptoms
• ABI ≤ 0.9 in the symptomatic leg
Exclusion criteria:
• Diabetes
• Impaired fasting glucose
• Peripheral vascular intervention within prior 6 months
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NCT01231360 (Continued)
• Recent unstable angina
• MI or stroke within prior 6 months
• Changes to HMG-CoA reductase inhibitor (statin) within past 3 months
• Changes to pentoxifylline and/or cilostazol regimen within past 3 months or anticipated to be
necessary during the study
• On Coumadin
• Exercise limitations for reasons other than IC (such as congestive heart failure, angina, chronic lung
disease, or other disorders affecting the limb such as arthritis or neuropathy)
• Rest pain or ulcers due to CLI
• Lower extremity amputation
Interventions Active comparator: exercise training
Participants randomised to exercise training will participate in a 3-month treadmill exercise programme in
1-h training sessions 3 times per week as previously described. After a 5-minute warm-up period, exercise
is initiated at a low workload of 2 mph at 0% grade. Participants walk until moderate claudication severity
develops, then rest until the discomfort resolves, repeating until the total exercise period is completed. The
intensity of treadmill exercise is increased as tolerated by increasing walking speed by 0.5 to 1 mph and/or
grade by 1% to 2%. Participants are encouraged to continue the walking programme at home for at least 30
minutes on 2 separate occasions each week
Active comparator: normal routine
Participants randomised to the routine activity control group will be asked to keep a log of their daily activities
and return to the Vascular Research Center at weeks 4, 8, and 12, at which time they will be asked to return
their log and undergo repeat treadmill testing and complete the 6-minute walking test
Outcomes Specific aim 1: to test the hypothesis that subjects with PAD and IC have altered expression of genes that
regulate skeletal muscle metabolism
Specific aim 2: to test the hypothesis that exercise training improves calf skeletal muscle insulin resistance and
genes that regulate skeletal muscle metabolic function in PAD patients with intermittent claudication
Starting date Estimated enrolment: 75
Study start date: October 2010
Estimated study completion date: June 2013
Estimated primary completion date: December 2012 (final data collection date for primary outcome measure)
Contact information Reena Pande, MD, Brigham and Women’s Hospital
skadivar@partners.org
Contact: 617-732-6320
Notes NCT01231360
NCT01822457
Trial name or title Effect of Nike Fuel Band on Exercise and Function in Claudicants: A Randomised Controlled Trial
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: supportive care
• Experimental: Nike Fuel Band (NFB). Participants will receive a Nike Fuel Band to encourage exercise.
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NCT01822457 (Continued)
• No intervention: control standard follow-up
Participants Inclusion criteria:
• Age 40 to 80 years
• Referred to vascular rehabilitation service at St Mary’s Hospital (UK)
• IC involving the calf muscles
• Clinical and duplex investigations indicate superficial femoral artery stenosis or occlusion
Exclusion criteria:
• Clinical and duplex investigations indicate iliac disease
• Major joint disease in lower limb or lumbar spine/entrapment syndrome
• Significant cardiopulmonary limitations (NYHA > 1)
• MWD > 500 m
• Hospital in-patient/living in a care home
• *Unfamiliarity with required technology
• History of dementia
• Inability to mobilise independently (does not include walking aids)
• IC not a limiting factor of mobilisation, limited by other medical problems
• Inability to attend supervised exercise programme
• Patient owns or uses any type of activity monitor
• Uses a walking frame
*Participants should be able to use the NFB technology with minimal assistance
Gender: both
Ages: 40 to 80 years
Interventions Device: Nike Fuel Band (NFB). The NFB is a wrist-worn sensor with a built-in accelerometer for motion
quantification. It is programmed to estimate the number of steps taken per day, and also to predict energy
expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and
monitor his or her activity through a graphical user interface
Outcomes All outcomes assessed at 3 months
Primary: MWD - standardised treadmill test
Secondary:
• PFWD - standardised treadmill test
• Disease-specific quality of life via the VascuQol Questionnaire
• Mood via the Hospital Anxiety and Depression Scale score
Starting date August 2013
Contact information Pasha Normahani: Pn106@imperial.ac.uk, Richard M Kwasnicki: rmk107@imperial.ac.uk
Notes Estimated completion: February 2015 (final data collection date for primary outcome measure)
ABI: ankle brachial index.
CLI: critical limb ischaemia.
HMG-CoA: rate-controlling enzyme of the mevalonate pathway.
IC: intermittent claudication.
mph: miles per hour.
MI: myocardial infarction.
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MWD: maximum walking distance.
NFB: Nike Fuel Band.
NYHA: New York Heart Association.
PAD: peripheral arterial disease.
PFWD: pain-free treadmill walking distance.
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D A T A A N D A N A L Y S E S
Comparison 1. Overall outcomes: exercise regimen compared with placebo or usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking distance (m) 10 500 Mean Difference (IV, Random, 95% CI) 120.36 [50.79, 189.
92]
2 Pain-free walking distance (m) 9 391 Mean Difference (IV, Fixed, 95% CI) 82.11 [71.73, 92.48]
3 Maximum walking time (min) 12 577 Mean Difference (IV, Random, 95% CI) 4.51 [3.11, 5.92]
3.1 Usual care 11 563 Mean Difference (IV, Random, 95% CI) 4.47 [3.00, 5.94]
3.2 Placebo 1 14 Mean Difference (IV, Random, 95% CI) 5.20 [0.88, 9.52]
4 Pain-free walking time (min) 11 534 Mean Difference (IV, Random, 95% CI) 2.93 [1.77, 4.09]
4.1 Usual care 10 520 Mean Difference (IV, Random, 95% CI) 3.08 [1.82, 4.34]
4.2 Placebo 1 14 Mean Difference (IV, Random, 95% CI) 1.77 [0.55, 2.99]
5 Change in MWD/T 15 656 Mean Difference (IV, Random, 95% CI) 40.25 [28.64, 51.86]
6 Change in ICD/T 15 703 Mean Difference (IV, Random, 95% CI) 58.42 [44.20, 72.64]
7 Ankle brachial index 13 570 Mean Difference (IV, Random, 95% CI) 0.04 [-0.00, 0.08]
8 Mortality 5 540 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.39, 2.17]
9 Amputation 1 177 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.15]
10 Peak exercise calf blood flow
(mL/100 mL/min)
4 103 Mean Difference (IV, Fixed, 95% CI) 0.94 [-0.81, 2.69]
10.1 Usual care 2 71 Mean Difference (IV, Fixed, 95% CI) 2.83 [0.18, 5.49]
10.2 Placebo 2 32 Mean Difference (IV, Fixed, 95% CI) -0.52 [-2.85, 1.82]
Comparison 2. Three-monthly outcomes: exercise regimen compared with placebo or usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking distance (m) 3 116 Mean Difference (IV, Random, 95% CI) 104.46 [-64.33, 273.
24]
2 Pain-free walking distance (m) 3 156 Mean Difference (IV, Fixed, 95% CI) 88.70 [58.25, 119.
15]
3 Maximum walking time (min) 5 172 Mean Difference (IV, Fixed, 95% CI) 6.05 [5.47, 6.62]
3.1 Usual care 5 172 Mean Difference (IV, Fixed, 95% CI) 6.05 [5.47, 6.62]
4 Pain-free walking time (min) 3 132 Mean Difference (IV, Fixed, 95% CI) 4.95 [4.38, 5.53]
5 Ankle brachial index 4 130 Mean Difference (IV, Fixed, 95% CI) 0.06 [0.01, 0.11]
6 Mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Quality of Life SF-36 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Physical function 2 82 Mean Difference (IV, Fixed, 95% CI) 6.60 [2.37, 10.83]
7.2 Bodily pain 2 82 Mean Difference (IV, Fixed, 95% CI) 3.89 [-1.91, 9.68]
7.3 General health 2 82 Mean Difference (IV, Fixed, 95% CI) 4.52 [-0.01, 9.04]
7.4 Mental health 2 82 Mean Difference (IV, Fixed, 95% CI) 1.44 [-0.93, 3.81]
7.5 Role emotional 2 82 Mean Difference (IV, Fixed, 95% CI) 1.26 [-4.84, 7.36]
7.6 Social function 2 82 Mean Difference (IV, Fixed, 95% CI) 1.49 [-4.16, 7.14]
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7.7 Vitality 2 82 Mean Difference (IV, Fixed, 95% CI) 5.55 [1.54, 9.56]
7.8 Role physical 2 82 Mean Difference (IV, Fixed, 95% CI) 10.31 [3.64, 16.98]
7.9 Physical Summary Score 1 29 Mean Difference (IV, Fixed, 95% CI) 2.58 [-4.29, 9.45]
7.10 Mental Summary Score 1 29 Mean Difference (IV, Fixed, 95% CI) 2.05 [-4.73, 8.83]
8 Peak exercise calf blood flow
(mL/100 mL/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Six-monthly outcomes: exercise regimen compared with placebo or usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking distance (m) 3 156 Mean Difference (IV, Random, 95% CI) 138.36 [22.39, 254.
34]
2 Pain-free walking distance (m) 2 116 Mean Difference (IV, Fixed, 95% CI) 52.14 [6.83, 97.45]
3 Maximum walking time (min) 4 295 Mean Difference (IV, Fixed, 95% CI) 3.20 [2.04, 4.36]
3.1 Usual care 3 281 Mean Difference (IV, Fixed, 95% CI) 3.05 [1.84, 4.25]
3.2 Placebo 1 14 Mean Difference (IV, Fixed, 95% CI) 5.20 [0.88, 9.52]
4 Pain-free walking time (min) 5 292 Mean Difference (IV, Random, 95% CI) 2.32 [0.91, 3.74]
4.1 Usual care 4 278 Mean Difference (IV, Random, 95% CI) 2.72 [0.67, 4.77]
4.2 Placebo 1 14 Mean Difference (IV, Random, 95% CI) 1.77 [0.55, 3.00]
5 Ankle brachial index 6 240 Mean Difference (IV, Random, 95% CI) 0.05 [-0.01, 0.11]
6 Mortality 1 178 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.54]
7 Quality of Life SF-36 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Physical summary score 5 429 Mean Difference (IV, Fixed, 95% CI) 2.15 [1.26, 3.04]
7.2 Mental summary score 4 343 Mean Difference (IV, Fixed, 95% CI) 3.76 [2.70, 4.82]
7.3 Physical function 2 85 Mean Difference (IV, Fixed, 95% CI) 9.78 [0.82, 18.74]
7.4 Bodily pain 2 85 Mean Difference (IV, Fixed, 95% CI) 4.85 [-3.79, 13.50]
7.5 General health 2 85 Mean Difference (IV, Fixed, 95% CI) 10.19 [1.83, 18.55]
7.6 Mental health 2 85 Mean Difference (IV, Fixed, 95% CI) 1.82 [-5.28, 8.92]
7.7 Role emotional 2 85 Mean Difference (IV, Fixed, 95% CI) 4.90 [-7.15, 16.94]
7.8 Social function 2 85 Mean Difference (IV, Fixed, 95% CI) 3.48 [-6.74, 13.71]
7.9 Vitality 2 85 Mean Difference (IV, Fixed, 95% CI) 5.32 [-2.57, 13.22]
7.10 Role physical 2 85 Mean Difference (IV, Fixed, 95% CI) 8.55 [-2.69, 19.79]
8 Peak exercise calf blood flow
(mL/100 mL/min)
2 66 Mean Difference (IV, Fixed, 95% CI) 3.79 [0.51, 7.07]
8.1 Usual care 1 52 Mean Difference (IV, Fixed, 95% CI) 3.10 [-0.46, 6.66]
8.2 Placebo 1 14 Mean Difference (IV, Fixed, 95% CI) 7.57 [-0.78, 15.92]
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Comparison 4. Exercise regimen compared with antiplatelet therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking time (min) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Ankle brachial index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Peak exercise calf blood flow
(mL/100 mL/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 5. Exercise regimen compared with pentoxifylline therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking time (min) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 6. Exercise regimen compared with iloprost therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Pain-free walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 7. Exercise regimen compared with pneumatic foot and calf compression
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Pain-free walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Mortality 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 8. Exercise regimen compared with vitamin E
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 3-monthly maximum walking
time (min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 6-monthly maximum walking
time (min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 3-monthly ABI 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 6-monthly ABI 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. Functional status and quality of life data (QoL) for all studies
Study Measure reported Effect reported
Collins 2005 Walking ImpairmentQuestionnaire (WIQ) - perceived
distance and walking speed
On the basis of analysis of change scores, the polestrid-
ing group reported significantly greater perceived abil-
ity to walk distance than the control group at 4 (P = 0.
05), 12 (P = 0.001), and 24 (P = 0.002) weeks. More-
over, the polestriding group rated their perceived ability
to walk faster to be significantly greater than the control
group at 4 (P = 0.03), 12 (P = 0.19), and 24 (P = 0.
02) weeks. The groups’ ratings were equivalent at base-
line (P > 0.05). In the polestriding group, polestriding
aggregate scores for both distance and speed improved
significantly between baseline and 12 weeks (P < 0.
0001) and baseline and 24 weeks (P < 0.0001), but not
between 12 and 24 weeks (P > 0.015). The perception
of walking speed and distance did not improve in the
control group
Rand Short Form-36 (SF-36) - perceived physical func-
tion
Exercise significantly improved the Physical Compo-
nent Summary score (PSS) of SF-36 when compared
with usual care. Difference using the change score be-
tween polestriding and control groups for the PSS was
significant; P = 0.03. There was no difference in the
change on the Mental Component Summary score be-
tween groups
Gardner 2002 Health-related quality of life (QoL) assessed with the
Medical Outcomes Study Short Form-36 (MOS SF-
36)
Baseline measures of health-related QoL were compa-
rable in both groups
The physical and mental health composite scores of the
MOS SF-36 were similar between the 2 groups and did
not change during the study. Consequently, no analyses
were performed on the individual subscales
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Table 1. Functional status and quality of life data (QoL) for all studies (Continued)
WIQ No change in the WIQ was identified. Baseline scores
on the 3WIQ subscales ranged between 32%and 52%.
Although the exercise group increased by 22%and34%
on the distance and speed subscales, respectively, these
changes were not significant and did not differ from
the changes in controls
Gelin 2001 Intermittent Claudication-specific Sickness Impact
Profile (SIP) scale, SIPIC
Supervised physical training produced significant im-
provements from baseline in only 2 health-related qual-
ity of life (HRQoL) domains (SIP Recreation and pas-
times (P <0.05) and the single-item rating scale Physical
Condition) and an ambiguous pattern of positive and
negative trends in others. Unexpectedly, deterioration
was most striking in functional health, where reduc-
tions appeared in 10 of 15 SIP categories. Compared
with no treatment, physical training produced signif-
icantly greater improvement in only 1 HRQoL cate-
gory: SIP recreation and pastimes. Improvement in this
category, however, may possibly be accounted for by
the opportunities for increased leisure activity afforded
by participation in the ongoing training programme
Health-related QoL, QoL overall No significant improvement was observed between
training and control groups. Training produced small
SRMs (mean change between assessments divided by
the standard deviation of change) (0.2 to < 0.5) on 4
HRQoL dimensions, of which 2 represented improve-
ment
Guidon 2010 Medical Outcomes Study Short Form-36 No significant differences between groupswere demon-
strated for any of theMOS SF-36 scores over the 3 time
points (baseline, 12 weeks, and 1 year). This study was
not included in the meta-analysis, as the MOS SF-36
differs from the standard SF-36 Questionnaire
Disease-specific QoL (ICQ) Results show a statistically significant decrease (P = 0.
003) in ICQ scores from baseline to 12-week follow-
up (mean difference -9.74, 95% CI -3.76 to -15.71)
in the exercise group, indicating improved quality of
life. No significant difference was demonstrated in the
control group
WIQ In the exercise group, increases were observed in all
WIQ scores, with a statistically significant increase (P =
0.015) in theWIQDistance score (mean difference 14.
28, 95%CI 2.96 to 25.61). In the control group, scores
for the WIQ Stair-climbing and Distance categories
decreased, with a marginal increase in the WIQ Speed
score. None of these changes were significant
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Table 1. Functional status and quality of life data (QoL) for all studies (Continued)
Kakkos 2005 Short Form-36 (SF-36) Score for the general health domain of the SF-36 was
significantly improved at 1 year in individuals who used
intermittent pneumatic compression (IPC). This study
was not included in themeta-analysis, as the full dataset
was not available in the study and could not be obtained
from the study author
WIQ IPC improved speed score of WIQ significantly. WIQ
scores for walking distance, walking speed, and stair
climbing were reduced in the unsupervised exercise
group, remained stable in the supervised exercise group,
and were increased in the IPC group
Intermittent Claudication Questionnaire (ICQ) Supervised exercise and IPC reduced (improved) the
ICQ score, but this was significant only in the IPC
group
McDermott 2008 WIQ Distance score improved (P = 0.02) in the treadmill
group when compared to the control group. This was
not apparent in the other 2 domains (speed and stair
climbing)
SF-36 physical functioning score Improved (P = 0.04) in the treadmill group when com-
pared to the control group
GOALS 2013 WIQ scores Participants in the intervention group, when compared
with those in the control group, improved their WIQ
distance score (35.3 to 47.4 vs 33.3 to 34.4; mean dif-
ference 11.1, 95% CI 3.9 to 18.1; P = 0.003) and their
WIQ speed score (36.1 to 47.7 vs 35.3 to 36.6; mean
difference 10.4, 95% CI 3.4 to 17.4; P = 0.004) but
not theirWIQ stair-climbing score (48.9 to 57.3 vs 47.
9 to 48.5; mean difference 7.9, 95% CI 0.00 to 15.8;
P = 0.05)
Physical Health Composite Score (PCS) and Mental
Health Composite Score (MCS) scales from the 12-
itemMedical Outcomes Study Short FormHealth Sur-
vey (SF-12)
Results show no between-group differences in change
in the SF-12 PCS or MCS subscales
Tew 2015 Intermittent Claudication Questionnaire (ICD) The intervention group demonstrated improvement in
the ICD score of -10.6 (95% CI -18.9 to - 2.3)
Tisi 1997 Nottingham Health Profile (NHP) A daily home exercise programme, supervised weekly
by a physiotherapist for the first month, achieves good
compliance, increased walking distances, and improved
quality of life as assessed by the Nottingham Health
Profile Questionnaire
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Table 1. Functional status and quality of life data (QoL) for all studies (Continued)
Tsai 2002 WIQ Improved speed (P < 0.001) and stairs (P < 0.001) in
the exercise group when compared to the control group
at 12 weeks. No significant difference in the distance
domain
SF-36 - version 1 Perception of QoL increased significantly in the exer-
cise group compared to usual care for the domains of
physical function, role limitation, bodily pain, general
health, and vitality. This study was included in the 3-
month meta-analysis; however the SF-36 version 1 dif-
fers from the standard SF-36 Questionnaire
Zwierska 2005 WIQ Improvement in all 3 domains was seen in the upper
limb group at 24 and 48 weeks when compared to
the control group. The lower limb group improved in
stair and speed domains at 24 and 48 weeks only when
compared to the control group
SF-36 - version 2 At 6 weeks, improvement in general health was seen in
the lower-limb group when compared to the control
group
At 24 weeks, a significant improvement was seen in
general health and vitality in the lower limbgroupwhen
compared to the control group. The upper limb group
significantly improved in physical function and mental
health when compared to the control group
WH A T ’ S N E W
Last assessed as up-to-date: 15 November 2016.
Date Event Description
15 November 2016 New citation required but conclusions have not
changed
Searches rerun, 2 new studies included, 18 additional
studies excluded. New author (AH) joined the review
team. Text updated to reflect current Cochrane stan-
dards. ’Summary of findings’ table added. Conclusions
not changed
15 November 2016 New search has been performed Searches rerun, 2 new studies included, 18 additional
studies excluded
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H I S T O R Y
Protocol first published: Issue 2, 1997
Review first published: Issue 1, 1998
Date Event Description
9 November 2013 New search has been performed Searches rerun, 11 new studies included, 45 additional
studies excluded
9 November 2013 New citation required but conclusions have not
changed
New author (RAL) joined the review team. Searches
rerun, 11 new studies included, 45 additional studies
excluded. Risk of bias tables completed for all included
studies
In comparison with previous versions of this review,
this version no longer focuses on supervised versus non-
supervised exercise, or invasive interventions compared
with exercise, as these are covered in other Cochrane
reviews
18 June 2008 New search has been performed 12 new trials considered. Conclusions confirm findings
of the previous review
29 April 2008 New citation required but conclusions have not
changed
Two new review authors
8 April 2008 Amended Converted to new review format
25 October 1999 New citation required but conclusions have not
changed
Substantive updates made
17 June 1998 New citation required and minor changes After consultation with GCL, original November 1997
version substituted for June 1998 ’update’, as latter was
an incorrect version. Some phrasing changed in June
1998, no changes to figures, so earlier version more
appropriate. Edited abstract added too (24.2.99)
C O N T R I B U T I O N S O F A U T H O R S
Risha Lane (RL): selected trials, assessed quality, extracted data, and revised text for the third and fourth updates.
Amy Harwood (AH): selected trials, assessed quality, and extracted data for the fourth update.
Lorna Watson (LW): commented on content of the fourth update.
Gillian Leng (GCL): commented on content of the fourth update.
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D E C L A R A T I O N S O F I N T E R E S T
RL: none known.
AH: none known.
LW: none known.
GCL: I am responsible for the National Institute for Health and Care Excellence (NICE) Implementation programme and I am the
Executive Director of NICE. I am a trustee of the Royal Society of Medicine and the Guidelines International Network.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since the time of the original protocol, various changes have had to be instigated with regards to bias assessments. These have moved
from the Schutlz assessment to Jadad and finally to the current Cochrane risk of bias assessment method (Higgins 2011). We have
reassessed all trials to comply with the current bias scoring system.
The protocol itself has not been altered; however we have applied strict adherence to the protocol with regards to usual care. As walking
advice has often been advocated as part of usual care, we have considered inclusion of only non-exercise control groups within this
review. This has been clarified and searched for in each paper, as walking advice would constitute unsupervised exercise, which was not
the focus of this review.
To avoid overlap with other existing Cochrane reviews (Antoniou 2017; Fowkes 1998), we removed from this review the comparisons
exercise versus angioplasty and exercise versus surgery.
In addition to planned treadmill walking distance and walking time, we have presented the results as a percentage change.
In keeping with current Cochrane policy, this version includes a ’Summary of findings’ table and GRADE assessment of the quality of
evidence. We have amended secondary outcomes to reflect clinical relevance.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Amputation [statistics & numerical data]; Ankle Brachial Index; Exercise Therapy [∗methods]; Intermittent Claudication [∗therapy];
Pain Management [methods]; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Walking
MeSH check words
Female; Humans; Male
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